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The Postpoliomyelitis Syndrome 
Poliomyelitis, or infantile paralysis, is an infectious viral disease that causes an acute, 
flaccid paresis of a varying number of muscle groups.1 Large epidemics occurred in 
the first half of the 20th century and affected mainly children under the age of five. In 
the mid-fifties vaccination became available, and although polio persisted in the 
developing countries, it became a ‘forgotten’ disease in the Western world.  
Although cases of late onset progressive muscle weakness following polio had 
occasionally been reported since the end of the 19th century,2 it was generally 
assumed that the residual neurological deficits resulting from polio would remain 
stable throughout life. However, in the late nineteen seventies large numbers of polio 
survivors of the epidemics in the fourties and fifties in the United States voiced new 
complaints.3,4 Inventory studies demonstrated that the main symptoms were new or 
progressive muscle weakness, severe fatigue, and pain in muscles and joints.5-7 Less 
common symptoms included muscle atrophy, difficulties with breathing and 
swallowing, sleep disorders, and cold intolerance. These symptoms were termed the 
postpoliomyelitis syndrome (PPS).8 The diagnostic criteria for PPS have changed 
over time,9-11 and the diagnosis of PPS is currently based on the general criteria 
presented in table 1.12 
 
The prevalence of late onset neuromuscular symptoms varies between 29% and 75% 
in population-based studies of polio survivors.13-16 This large variation depends on the 
methodological differences between studies with regard to the selection of the study 
populations, the definition of the symptoms, and the methods of assessment. In a 
population-based study that was carried out in 1995 to investigate 260 former victims 
of the 1956 polio outbreak in the Netherlands, 58% of the respondents reported that 
their muscle weakness had increased.17 Since 1924, 14,682 casesa of poliomyelitis 
have been reported to the national health authorities in the Netherlands. 
The course of PPS is slowly progressive, and the rate of decline in muscle strength 
is assumed to be slow. Studies with a follow-up of less than 4 years did not 
demonstrate any progression of muscle weakness,18-20 but data from longer term 
studies indicate a decline in strength of approximately 1-2% per year.21,22  
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PPS negatively affects functioning in daily life. Growing restrictions in the ability to 
perform activities are mainly found for mobility-related activities such as walking, 
climbing stairs, and transfers.5,7,14,23-25 Mobility problems affect the level of 
independence and also decrease life satisfaction.26 The physical functioning of 
patients with PPS was found to decline over a 6-year period.27 Over a period of 4-5 
years, a significant increase in the degree of handicap with regard to mobility, 
occupation, and social integration was found in PPS subjects, while in non-PPS 
subjects the degree of handicap remained unchanged.28 
 
Table 1 Criteria for postpoliomyelitis syndrome 
 
1)  Prior paralytic poliomyelitis with evidence of motor neuron loss, as confirmed by 
history of the acute paralytic illness, signs of residual weakness and atrophy of 
muscles on neurologic examination, and signs of denervation on 
electromyography 
2)  A period of partial or complete functional recovery after acute paralytic 
poliomyelitis, followed by an interval (usually 15 years or more) of stable 
neurologic function 
3)  Gradual or sudden onset of progressive and persistent new muscle weakness or 
abnormal muscle fatigability (decreased endurance), with or without generalized 
fatigue, muscle atrophy, or muscle and joint pain 
4)  Symptoms persist for at least one year 
5)  Exclusion of other neurologic, medical and orthopedic problems as causes of 
symptoms 
 
Pathophysiology 
Acute paralytic poliomyelitis develops in 0.1-2% of all infections when the polio virus 
invades the central nervous system and predominantly destructs the spinal motor 
neurons.1 In severe cases, affection of the brain stem may result in death. 
The acute stage of polio is followed by a period of neurological and functional 
recovery that may last for several months to years.1 During this period, the affected 
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motor neurons that have survived the acute stage recover and regain their function. 
Denervated muscle fibres from permanently destroyed motor neurons are 
reinnervated through collateral sprouting from surviving axons, and motor units may 
increase five to eight times in size.29-32 Strength also improves because of muscle 
fibre hypertrophy,33-35 and fibre areas may increase up to twice the normal size.35 It is 
assumed that muscle fibre hypertrophy develops in response to the relatively heavy 
load on paretic muscles in performing daily life activities.34 At the end of the recovery 
period, a varying degree of residual paresis remains. This situation usually lasts for 
several decades, providing stable muscle strength and functioning. 
The most widely accepted hypothesis for PPS was presented by Wiechers and 
Hubbell.36,37 They assumed that the enlarged motor units would not remain stable 
throughout life, but degenerate prematurely due to persistent, high metabolic stress 
on the motor neurons. The degeneration of these motor units causes a slowly 
progressive loss of axonal sprouts. This concept has been confirmed through the 
finding of single atrophic muscle fibres in muscle biopsy studies.34,38,39 
In addition, whole motor units may also collapse. In a prospective study estimating 
the number of motor units the rate of motor unit loss in prior poliomyelitis patients was 
twice the rate of motor unit loss in healthy subjects over 60 years of age.40 However, 
a loss of entire motor units is not a common observation in muscle biopsy studies.34,39 
Moreover, muscle strength declines slowly over time.21,22 Therefore, new muscle 
weakness in PPS is primarily the result of isolated degeneration of motor nerve 
terminals. 
 
Jubelt and Cashman suggested that during an intervening period before 
degeneration, which may last for weeks to years, the terminal axons do not function 
properly, and complaints such as fatigue and lack of endurance may be due to 
dysfunction of terminal axons rather than degeneration.41 Dysfunction of terminal 
axons was confirmed in stimulation single fibre electromyography (S-SFEMG) studies 
that found signs of neuromuscular transmission defects such as increased jitter and 
blockings.42,43 It appeared that 10-20% of neuromuscular junctions in the 
symptomatic muscles of PPS patients were below the threshold for effective 
transmission. Trojan and Cashman discovered that jitter significantly increased at 
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high stimulation rates during S-SFEMG.44 This finding suggests that the terminal 
axonal dysfunction is partly due to a defect in the release of the neurotransmitter 
acetylcholine. 
Another factor that may contribute to new muscle weakness is an impaired ability 
to activate the muscles.45 Impaired activation has been found significantly more often 
in prior polio patients with PPS than in prior polio patients with no new symptoms.46,47 
This may be due to the late impairment in motor unit functioning, or it may be the 
result of an impaired reflex drive.48 
 
Pharmacological treatment for PPS 
Since there is no curative treatment for PPS, the management of PPS essentially 
aims to preserve the remaining muscle capacity and to prevent overloading of the 
symptomatic muscles. Multidisciplinary rehabilitation programmes usually consist of a 
combination of exercises, assistive devices, environmental adaptations, and changes 
in life-style. Several studies recommend non-fatiguing exercises to improve strength 
and endurance in patients with PPS.49-51 Assistive devices, such as braces and 
crutches, may also be helpful to support weak muscles and to stabilize joints.52,53 
Changes in life style include the pacing of activities and the integration of rest 
intervals to relieve the symptoms.54 
In addition to conservative treatment for PPS, a number of pharmacological agents 
have been tested (table 2). Human growth hormone55,56 and insulin-like growth factor-
157 were tested because they promote protein synthesis in muscle cells and axonal 
sprouting. Amantadine58, bromocriptine59, and selegiline60 are three centrally acting 
dopaminergic agonists that were tested to diminish fatigue, and high-dose 
prednisone61 was tested for its strong anti-inflammatory effect. Positive treatment 
effects were only found in studies with an open design or with a small sample 
size.55,59,60 No medication has been proven to increase strength or decrease fatigue 
in patients with PPS in a randomised controlled trial. 
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Pyridostigmine 
In the early nineties, Trojan and co-workers found that neuromuscular transmission 
defects in PPS patients could be ameliorated by injecting edrophonium (an 
anticholinesterase) into symptomatic muscles.62 They also investigated oral use of 
the anticholinesterase Pyridostigmine (Mestinon), a drug used to treat muscle 
fatigability in myasthenia gravis.63 Pyridostigmine inhibits the breakdown of 
acetylcholine by the enzyme cholinesterase, thereby prolonging the survival and 
effect of acetylcholine in the neuromuscular junction. Pyridostigmine may directly 
decrease fatigue and increase strength by restoring effective transmission in blocked 
or defective neuromuscular junctions.62,64 In the longer term, pyridostigmine may 
increase strength by promoting secretion of the human growth hormone and, 
consequently, trophic growth factors such as insulin-like growth factor-1.65  
Two open trials of pyridostigmine demonstrated a decline in fatigue, and reported a 
significant relationship between the decline in fatigue and the improvement in 
neuromuscular transmission.62,66 In a placebo-controlled cross-over trial (published 
as an abstract) a mild improvement in the strength of weak muscles was found.67 
In 1999, the results of the North American postpoliomyelitis pyridostigmine study 
were published by Trojan and co-workers.68 This was a randomised, double-blind, 
placebo-controlled multicenter trial in 126 PPS patients. It was found that 180 mg 
pyridostigmine per day for a period of 6 months had no effect on physical functioning 
(measured with the Short Form Health Survey-36), muscle strength (measured with 
the Tufts Quantitative Neuromuscular Examination) or fatigue (measured with the 
Fatigue Severity Scale and the Hare Fatigue Symptom Scale). The negative results 
of this multicenter trial may imply that pyridostigmine is not effective in the treatment 
of PPS. On the other hand, the negative results may also be due to methodological 
limitations of the study design with respect to patient selection, outcome measures 
and the dosage of pyridostigmine.69 
 
Purpose of this thesis 
Given the limitations of the North American postpoliomyelitis pyridostigmine study, a 
randomised controlled trial (RCT) is carried out, which includes detailed 
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measurements and a higher dosage of pyridostigmine for selected patients with PPS. 
The results of this study are reported in this thesis.70 PPS patients with severe fatigue 
and with neuromuscular transmission defects, as demonstrated by S-SFEMG, are 
included in the study, because they are expected to benefit most from pyridostigmine. 
The outcome measures are chosen at the levels of perceived health, physical 
performance, and muscle function. This makes it possible to investigate the 
effectiveness of the treatment on different levels of functioning, as well as the 
relationships between the effects on these different levels. The primary outcome is 
fatigue, measured with the Nottingham Health Profile,71 a validated and widely 
accepted health-related quality of life scale that has been used in several studies of 
PPS patients.25,72,73 The Nottingham Health Profile was found to be responsive in an 
RCT with fibromyalgia patients.74 Secondary outcomes include measurements of 
physical performance, such as timed walking tests and walking activity in the daily 
environment, and measurements of muscle function, such as muscle strength, 
muscle fatigability, and maximal voluntary muscle activation. During the medication 
period neuromuscular transmission is investigated to assess the pharmacological 
effectiveness of 60 mg of pyridostigmine 4 times per day, which is 60 mg per day 
higher than the dosage prescribed in the North American postpoliomyelitis 
pyridostigmine study. 
A further aim of this thesis is to investigate the validity and reproducibility of the 
main outcome measures used in the trial to measure fatigue, walking performance, 
and muscle strength. The outcome measures should measure the symptom of 
interest reliably, and should also be sensitive enough to identify clinically relevant 
changes. 
 
Outline of this thesis 
This thesis describes the results of a randomised, double-blind, placebo-controlled 
trial investigating the effect of pyridostigmine on fatigue, physical performance and 
muscle function in patients with PPS, and focuses on the validity and reproducibility 
of the main outcome measures used in this trial. 
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Chapter 2 contains detailed comments on the results of the North American 
postpoliomyelitis pyridostigmine study carried out by Trojan and colleagues, and 
introduces the plan to set up a new trial. 
Chapter 3 investigates the validity and reproducibility of four questionnaires that 
have recently been used to determine the severity of fatigue in patients with PPS: the 
Fatigue Severity Scale; the energy category of the Nottingham Health Profile; the 
Fatigue item of the Polio Problem List; and the Short Fatigue Questionnaire. 
Concurrent and construct validity (Mokken scale analysis) are investigated, and the 
ability to detect change is assessed, as well as the effect of sample size on the ability 
to detect change. 
Chapter 4 investigates the reproducibility of measurements of maximal strength 
and maximal voluntary activation of symptomatic quadriceps muscles, using a fixed 
dynamometer. Variability in voluntary activation may contribute to the variability in 
muscle performance. Therefore, the association between variability in strength and 
voluntary activation is determined. 
In Chapter 5, the reproducibility of walking performance and physical effort is 
determined in two walking tests: one at self-preferred speed and one at maximal 
speed. Physical effort is measured by means of heart rate and the patient’s rating of 
perceived exertion (Borg scale). The association between the variability in walking 
performance and the variability in physical effort is investigated, and the 
appropriateness of perceived exertion for monitoring and pacing activities is 
discussed. 
Chapter 6 describes the results of the randomised, double-blind, placebo-
controlled trial of pyridostigmine in 67 patients with PPS who have an increased level 
of fatigue and demonstrated neuromuscular transmission defects in a symptomatic 
quadriceps muscle. The primary outcome is perceived fatigue, measured with the 
energy category of the Nottingham Health Profile. Secondary objectives are to 
investigate the effects on physical performance and muscle function. 
Chapter 7 investigates whether walking in a clinical setting reflects effort levels and 
characteristics such as step cadence and speed of normal walking in daily life. In 
addition, relationships are determined between walking test performance, the amount 
of walking in daily life, and perceived physical mobility problems. 
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Chapter 8 discusses the results of the randomised controlled trial and the 
appropriateness of the main outcome measures used in the trial. Suggestions are 
made for the treatment of, and the evaluation of treatment effects in patients with 
PPS in the future. 
 
a Data provided by J.K. van Wijngaarden, MD; Inspectorate for Health Care of the 
Ministry of Health, The Hague, The Netherlands. 
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o substantial beneficial effect of pyridostigmine in patients with postpoliomyelitis 
syndrome (PPS) was found by Trojan et al.1 This negative result is 
disappointing, because its potential benefit has been shown in previous studies,2,3 
and fatigue and walking difficulties are major problems in PPS.4  
Although the trial was a well designed, double-blind study, its weakness seems 
primarily to be the lack of responsiveness of the outcome measures. These measures 
were probably chosen for pragmatic reasons, as the measurements had to be carried 
out at different sites. A multicenter design has the advantage of collecting enough 
patients to achieve sufficient statistical power within an acceptable time-frame. 
Unfortunately, this probably accounts for the negative results that, for most outcome 
measures, might have been foreseeable. The lack of responsiveness of the short 
form health survey-36 (SF-36), as discussed by the authors, has been confirmed in 
the evaluation of a rehabilitation treatment program in patients with MS.5 The SF-36 
probably only detects large changes; for instance, in patients who deteriorate 
rapidly.6 Although correlation coefficients of reproducibility for the fatigue scales were 
high, they give no information about the ability to detect change.7  
At best, pyridostigmine could be expected to cause relatively small changes in 
strength. The fact that the average pretrial intra-rater differences for the Tufts 
Quantitative Neuromuscular Examination measurements were below 10% provides 
no information about the smallest mean difference that could be detected without 
mentioning the standard error. Presenting changes in strength as a percentage 
change from baseline values amplifies changes in weak muscles tremendously. For 
instance, with a strength of 10N, an increase of 5N represents a 50% change, 
whereas the same increase at 100N would imply only a 5% change. Table 31 shows 
that the percentage change in strength decreases with increasing relative strength. 
Thus, the nonsignificant change of 41.8% in very weak muscles may seem large, but 
is in fact very small in Newtons. 
 
The study illustrates that the step from open, sophisticated, electrophysiologic studies 
to a multicenter trial with global outcome measures may be too big. If the results are 
negative, considerable thought should be given to the possible shortcomings of the 
study. Although criticizing in retrospect is relatively easy, it may have been better to 
N 
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first study the effect of pyridostigmine in a double-blind trial in a homogeneous group 
of patients, all who exceed a predefined level of fatigue and who demonstrate 
transmission defects in a symptomatic muscle group that is functionally important, 
and in which strength can be measured reliably.  
In April 1999 we started such a study, which involves a fatigue protocol, functional 
performance tests, and electromyography of motor-unit remodeling, which may be an 
important effect modifier. If the results in selected patients are positive, the next step 
would be to investigate the generalisability. As stated by Dalakas,8 exercise and 
reassurance are important measures, but the bottom-line of treatment for PPS is still 
the pacing of activities. In the near future we hope to respond to the final remarks of 
Trojan et al.1 Excluding pyridostigmine as a possible beneficial treatment for PPS 
patients seems, at present, to be too premature. 
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ABSTRACT 
Objective: To assess the comparability and reproducibility of 4 questionnaires used to 
measure fatigue in postpoliomyelitis syndrome (PPS).  
Design: Repeated-measures at a 3-week interval.  
Setting: University hospital.  
Participants: Convenience sample of 65 patients with PPS.  
Interventions: Not applicable.  
Main outcome measures: The Fatigue Severity Scale (FSS), the Nottingham Health 
Profile (NHP) energy category, the Polio Problem List (PPL) fatigue item, and the 
Dutch Short Fatigue Questionnaire (SFQ).  
Results: Correlations of scores between questionnaires were all significant (P<.01) 
and ranged from .43 (between the NHP energy category and the PPL fatigue item) to 
.68 (between the PPL fatigue item and the SFQ). Scores on the second visit, 
normalised to a 0 to 100 scale, were: FSS, 78±15; NHP energy category, 47±35; PPL 
fatigue item, 81±17; and SFQ, 65±22. Except for the difference between the FSS and 
the PPL fatigue item, the differences in scores between the questionnaires were 
significant (P<.01). Scale analysis indicated that all questionnaires measured the 
same unidimensional construct. The reproducibility of the FSS, the PPL fatigue item, 
and the SFQ was moderate. The smallest detectable change was 1.5 points for the 
FSS, and 2 points for the PPL fatigue item and the SFQ.  
Conclusions: Although the questionnaires measure the same fatigue construct in 
PPS, the results are not interchangeable because the ranges of measurement differ. 
The NHP energy category, in particular, appeared to have a high detection threshold. 
The moderate reproducibility of the questionnaires indicates a lack of precision, 
especially when applied at the individual patient level. 
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ne of the major problems in postpoliomyelitis syndrome (PPS) is fatigue.1,2 
Approximately 66% to 89% of patients with PPS perceive symptoms of 
increased fatigue,3-5 which may lead to a decline in their physical activities6,7 and 
social functioning.1,8 In studies in which the severity of fatigue in PPS was measured, 
different group scores have been reported.2,6,7,9-13 However, fatigue was assessed 
with different questionnaires. Comparing results obtained with different 
questionnaires in the various studies is problematic, because it is not known whether 
the differences in scores reflect differences in the severity of fatigue between the 
study populations or differences in the response characteristics of the questionnaires. 
Items may differ in the range for which they measure the severity of fatigue. 
Furthermore, items may assess different aspects of fatigue─for example, some items 
measure fatigue associated with exertion and other items measure the perception of 
fatigue.14 Therefore, differences in the construct of fatigue may be present both within 
and between the questionnaires.  
Because fatigue has been used as an outcome measure, both in the treatment15-18 
and prospective follow-up studies of PPS,19 another important aspect that needs to 
be addressed is whether questionnaires that measure fatigue are reliable and 
sensitive enough to detect change.20  
 
Our study was undertaken to investigate the comparability and reproducibility of 4 
questionnaires that have been used to assess the severity of fatigue in PPS: the 
Fatigue Severity Scale (FSS), the energy category of the Nottingham Health Profile 
(NHP), the fatigue item on the Polio Problem List (PPL), and the Short Fatigue 
Questionnaire (SFQ). The comparability of the 4 questionnaires was investigated by 
determining their concurrent and construct validity. The reproducibility of the FSS, the 
PPL fatigue item, and the SFQ was investigated by determining the test-retest 
reliability and the smallest detectable change.  
 
O 
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METHODS 
Study population 
Sixty-five patients with PPS were recruited from the Dutch Neuromuscular Diseases 
Association (Vereniging Spierziekten Nederland), (academic) hospitals, and 
rehabilitation centers. All patients met the following inclusion criteria: (1) PPS, 
according to the Halstead criteria,21 that is, a history of paralytic polio, a period of 
neurologic recovery followed by an interval of functional stability of at least 15 years, 
and the onset of weakness in previously affected and/or unaffected muscles not due 
to inactivity, possibly accompanied by excessive fatigue, muscle pain, decreased 
endurance, and atrophy; (2) symptoms of increased fatigue, that is, a minimum score 
of 10 on the SFQ, which is above the normal values in a healthy Dutch population; (3) 
age 18 to 70 years; and (4) no other diseases that could cause the symptoms. The 
patients underwent a medical examination to check the criteria, and all participants 
gave written informed consent.  
 
Questionnaires 
Fatigue Severity Scale. The FSS consists of 9 statements that are scored on a 7-
point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). For each 
subject, a total score is calculated as the mean score of the 9 statements. A lower 
total score indicates less effect of fatigue on everyday life. The FSS has shown good 
internal consistency (Cronbach α range, .81–.95)22-24 and test-retest reliability in 
patients with multiple sclerosis or systemic lupus erythematosus (Pearson r=.84),22 
immune-mediated polyneuropathies (intraclass correlation coefficient [ICC]=.86),23 
and chronic hepatitis C (ICC=.82).24  
Nottingham Health Profile. The NHP energy category is 1 of the 6 categories of the 
NHP and consists of 3 yes-no questions. The category score is calculated by dividing 
the number of questions answered with yes by the total number of questions and 
multiplied by 100, which results in a score ranging from 0 (no complaints) to 100 
(answered yes to all questions). The Dutch version of the NHP energy category has 
shown satisfactory internal consistency (Cronbach α=.77)25 and test-retest reliability 
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(Spearman ρ range, .77–.86) in patients with chronic heart failure and myocardial 
infarction or stroke.25,26  
Polio Problem List. The PPL fatigue item is 1 of the 16 items on the PPL.2 The PPL 
fatigue item assesses the extent to which fatigue is perceived as a problem, and it is 
scored on an 8-point Likert scale, ranging from 0 (no problem) to 7 (severe problem).  
Short Fatigue Questionnaire. The SFQ consists of 4 statements that are scored on 
a 7-point Likert scale, similar to the scale of the FSS. For each subject, a total score 
is calculated as the mean score of the 4 statements. The SFQ has shown good 
internal consistency (Cronbach α=.88) and was found able to discriminate between 
patients and healthy subjects.27  
 
Assessment protocol 
Two study visits to the hospital were scheduled on the same day of the week and at 
the same time, with a 3-week interval. The questionnaires were administered once on 
each study visit, except for the NHP, which was administered only on the second 
occasion. Before each visit, the patients received brief instructions on how to 
complete each questionnaire. They were asked to score only for the previous 2 
weeks. The subjects were seated in a quiet room and were allowed to take all the 
time they needed to fill in the questionnaires and to rest in between, if necessary. In 
general, the time needed to fill in the questionnaires was less than 15 minutes. On 
both visits, the questionnaires were administered in the same order.  
 
Data analysis 
Validity was assessed on the basis of data obtained during the second study visit.  
Concurrent validity. Correlations between the scores of the different questionnaires 
were determined by calculating the Spearman rank correlation coefficients. To 
determine whether there were any systematic differences between the scores of the 
questionnaires, the normalised scores of the questionnaires (on a 0–100 scale) were 
compared, using the Friedman analysis of variance (ANOVA). Post hoc (pairwise) 
comparisons were made, using Wilcoxon signed-rank tests corrected for multiple 
testing (α=.05/6, with 6 pairs tested).28  
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Construct validity. To investigate the construct validity of the questionnaires, a 
Mokken scale analysis for polytomous itemsa was performed to determine the single 
scale homogeneity of the 17 items of the 4 questionnaires.29 Mokken scale analysis is 
a nonparametric approach to the item response theory.30 The concept of 
homogeneity refers to the Mokken model of monotone homogeneity, which assumes 
that the items measure the same construct, that item and item-step scores are locally 
independent, and that the item and the item-step response functions are monotonely 
nondecreasing functions of the latent trait.29 The Loevinger H scalability coefficient 
gives an indication of the extent to which the set of items form a homogeneous scale. 
An H smaller than .30 indicates a nonhomogeneous scale; between .30 and .40, 
weak homogeneity; between .40 and .50, moderate homogeneity; and greater than 
.50, strong homogeneity.29 The stronger the homogeneity, the more all items 
measure the same construct and the better the items discriminate between individual 
different positions on the construct. Homogeneous scales are considered to be 
unidimensional. Unlike dichotomous items, it is not possible to place polytomous 
items in hierarchic order with respect to the latent trait, because the order depends on 
both the item response functions and the item-step response functions.  
Reproducibility. Systematic differences between the 2 study visits were 
investigated for the total scores of the FSS and the SFQ using t tests and for the PPL 
fatigue item and item scores of the FSS and the SFQ using Wilcoxon signed-rank 
tests. The distribution of the FSS and SFQ scores was considered normal. The test-
retest reliability of the FSS and the SFQ was assessed with ICCs and the 95% 
confidence intervals (CIs) of the ICCs, using a random-effects 1-way ANOVA.31 Test-
retest reliability of the PPL fatigue item was analyzed by calculating the Spearman 
correlation coefficient. The internal consistency of the FSS, the NHP energy category, 
and the SFQ on the 2 study visits was determined with the Cronbach α coefficient. An 
α coefficient of .70 is considered sufficient, and an α coefficient of more than .80 is 
considered good for the purpose of group comparisons.32  
Test-retest reliability for the 3 questionnaires was also assessed by means of 
Bland-Altman plots, in which for each subject the difference between the scores of 
the 2 visits was plotted against the mean of these 2 scores.33 The 95% limits of 
agreement (mean difference ± 2 standard deviations [SDs]) were calculated for each 
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questionnaire to assess the smallest detectable change, which gives an indication of 
the change that is needed to detect a real change, taking chance variation or 
measurement error into account.34 A questionnaire is able to detect an individual 
change in score if the change lies outside the limits of agreement.  
For comparison of a group score in a paired situation, the smallest detectable 
change depends on the sample size. The effect of sample size on the smallest 
detectable change was estimated from n>k·σ2/∆2, with n being the number of 
subjects, k the constant based on tables of standard normal curve (k=10.51 for α=.05 
and β=.10), σ2 the variance of differences, and ∆ the smallest detectable change.35 
Statistical analysis was performed with the SPSS, version 10.0.5, statistical software 
package.b An α level of P less than .05 was used for all tests of significance.  
 
RESULTS 
Sixty-five patients (42 women, 23 men) with a mean age of 52±8 years completed the 
questionnaires on both visits. The mean time since the onset of polio was 49±8 
years, and the mean time since new neuromuscular symptoms were perceived was 
10±6 years. The total score and the item scores of the questionnaires on the first and 
second study visits are presented in table 1. The highest item scores on the FSS 
were found on the second visit for items 6 (“My fatigue prevents sustained physical 
functioning”; score, 6.3±1.0) and 8 (“Fatigue is among my three most disabling 
symptoms”; score, 6.2±1.3). The highest scores on the NHP energy category were 
found for items 1 (“I’m tired all the time”; score, 58±50) and 3 (“I soon run out of 
energy”; score, 62±49). The highest score on the SFQ was found on the first visit for 
item 2 (“I tire easily”; score, 5.9±1.3).  
 
Concurrent validity 
Pairs of total scores of questionnaires correlated significantly (P<.01), with the 
highest correlation coefficient of .68 between the PPL fatigue item and the SFQ and 
the lowest correlation coefficient of .43 between the NHP energy category and the 
PPL fatigue item (table 2).  
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Table 1 Total and item scores on the first and second study visits 
    
 First visit Second visit P value 
FSS (range, 1–7) 5.4±1.1 5.7±0.9 .03 
1. My motivation is lower when I am fatigued 5.0±1.9 5.3±1.8 .22 
2. Exercise brings on my fatigue 5.8±1.5 5.8±1.3 .93 
3. I am easily fatigued 5.6±1.6 5.9±1.3 .02 
4. Fatigue interferes with my physical 
functioning 
5.7±1.6 5.9±1.1 .15 
5. Fatigue causes frequent problems for me 4.4±1.7 4.9±1.7 .03 
6. My fatigue prevents sustained physical 
functioning 
5.9±1.7 6.3±1.0 .10 
7. Fatigue interferes with carrying out certain 
duties and responsibilities 
5.3±1.7 5.5±1.5 .40 
8. Fatigue is among my three most disabling 
symptoms 
6.1±1.4 6.2±1.3 .56 
9. Fatigue interferes with my work, family, or 
social life 
5.3±1.7 5.2±1.8 .43 
NHP energy category (range, 0–100)  47±35  
1. I’m tired all the time  58±50  
2. Everything is an effort  22±41  
3. I soon run out of energy  62±49  
PPL fatigue item (range, 0–7) 5.5±1.4 5.7±1.2 .05 
SFQ (range, 1–7) 5.0±1.2 4.9±1.3 .72 
1. I feel tired 4.9±1.5 4.9±1.7 .90 
2. I tire easily 5.9±1.3 5.8±1.5 .12 
3. I feel fit 5.0±1.6 5.1±1.6 .43 
4. I feel physically exhausted 4.0±1.9 3.9±1.9 .57 
Values are mean ± SD. Differences between study visits were investigated for the total scores of the 
FSS and the SFQ using t tests, and for the PPL fatigue item and item scores of the FSS and the SFQ 
using Wilcoxon signed-rank tests. 
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The normalised total and item scores of the questionnaires on the second study visit 
are given in table 3, and the normalised total scores are also presented in boxplots 
(figure 1). The mean normalised total scores were highest for the PPL fatigue item 
(81±17) and lowest for the NHP energy category (47±35). The mean normalised total 
scores for the FSS were 78±15, and for the SFQ they were 65±22. The normalised 
total scores of the questionnaires differed significantly (Friedman test, P<.01). 
Pairwise comparisons of the total scores of the questionnaires showed differences for 
all pairs of questionnaires (P<.05), except for the FSS-PPL fatigue item pair.  
 
Table 2 Spearman correlation coefficients 
     
 FSS NHP energy 
category 
PPL fatigue 
item 
SFQ 
FSS 1.00*    
NHP energy category 0.50* 1.00*   
PPL fatigue item 0.60* 0.43* 1.00*  
SFQ 0.47* 0.67* 0.68* 1.00 
*Significant correlation (P<.01). 
 
Construct validity 
Scale analysis performed on the 17 items of the 4 questionnaires showed that 15 of 
the 17 items formed a unidimensional scale (H=.49). The first 2 items of the FSS did 
not fit into this scale and did not form a separate scale (H=-.11). When scale analysis 
was performed on the FSS as a separate scale, once again the first 2 items misfitted. 
The item H for item 1 (“My motivation is lower when I am fatigued”) was .05, and the 
item H for item 2 (“Exercise brings on my fatigue”) was -.05. Scale analysis on the 
remaining 7 items of the FSS showed H equal to .63.  
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Table 3 Normalised total and item scores (range, 0–100) on the second study visit 
     
 Mean±SD 25 50 75 
FSS 78±15 70 80 88 
1. My motivation is lower when I am fatigued 71±30 67 83 100
2. Exercise brings on my fatigue 79±22 75 83 100
3. I am easily fatigued 82±22 75 83 100
4. Fatigue interferes with my physical functioning 82±18 67 83 100
5. Fatigue causes frequent problems for me 64±28 50 67 83 
6. My fatigue prevents sustained physical functioning 88±17 83 100 100
7. Fatigue interferes with carrying out certain duties 
and responsibilities 
74±25 67 83 100
8. Fatigue is among my three most disabling 
symptoms 
87±21 83 100 100
9. Fatigue interferes with my work, family, or social 
life 
69±30 50 83 100
NHP energy category 47±35 33 33 67 
1. I’m tired all the time 58±50 0 100 100
2. Everything is an effort 22±41 0 0 0 
3. I soon run out of energy 62±49 0 100 100
PPL fatigue item 81±17 71 86 93 
SFQ 65±22 50 71 83 
1. I feel tired 65±28 50 67 83 
2. I tire easily 79±25 67 83 100
3. I feel fit 68±27 50 67 83 
4. I feel physically exhausted 48±32 17 50 83 
Total and item scores are mean ± SD and quartiles. 
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Figure 1 Boxplots of normalised total scores (scale range, 0–100) on the second study 
visit. The box represents the interquartile range with the bold line as median value. 
The whiskers represent the range of the scores. Abbreviations: NHPE, NHP energy 
category; PPLF, PPL fatigue item.  
 
Reproducibility 
The total score of the FSS was higher on the second study visit than on the first 
(mean difference, 0.2±0.8; P=.03) (table 1). The score increased significantly for 
items 3 (“I am easily fatigued”; P=.02) and 5 (“Fatigue causes frequent problems for 
me”; P=.03). The total and item scores of the PPL fatigue item and the SFQ did not 
differ on retest. The ICCs (95% CI) for the FSS and the SFQ were .83 (.72–.90) and 
.84 (.73–.90), respectively. The Spearman ρ for the PPL fatigue item was .80 (P<.01).  
The FSS showed good internal consistency on the 2 study visits (Cronbach α=.85 
and .80, respectively). The internal consistency of the NHP energy category on the 
second study visit (Cronbach α=.59) was below the .70 standard recommended for 
group comparisons.32 The SFQ showed reasonable internal consistency on both 
study visits (Cronbach α=.79 and .77, respectively).  
The mean of the individual scores on the 2 study visits was plotted against the 
difference of the scores on both visits for the FSS, the PPL fatigue item, and the SFQ 
(figure 2). The 95% limits of agreement, when expressed as a percentage of the 
mean of 2 study visits, were narrowest for the FSS and widest for the SFQ (table 4). 
The effect of sample size on the smallest detectable change is presented in table 5. 
FSS SFQ PPLF NHPE 
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For comparison of a group score in a paired situation, changes of less than 10% on 
the FSS, the PPL fatigue item, and the SFQ were required for sample sizes of at least 
50 subjects.  
 
Table 4 Limits of agreement 
    
 Mean of scores  
of the 2 study visits 
Difference in scores 
of the 2 study visits 
95% Limits of agreement 
FSS (range, 1–7) 5.6±0.9 0.2±0.8  -1.3 to 1.7 (-23% to 31%) 
PPL fatigue item 
(range, 0–7) 
5.6±1.2 0.2±0.9  -2.0 to 2.0 (-36% to 36%) 
SFQ (range 1–7) 4.9±1.2 -0.0±1.0  -2.0 to 1.9 (-40% to 38%) 
The mean of the scores and the difference in scores of the 2 study visits are mean ± SD. The 
difference is calculated as scores on the second study visit minus scores on the first study visit. The 
95% limits of agreement are calculated as mean difference ±2 SDs of the difference and are 
expressed in original scale points and as a percentage of the mean of the 2 study visits. 
 
DISCUSSION 
Different questionnaires have been used to assess the severity of fatigue in PPS. 
However, little is known about the comparability and reproducibility of their results. In 
our study, both the validity and the reproducibility of various fatigue questionnaires 
were assessed in 65 patients with PPS. The data on reproducibility also provided 
information about the smallest detectable change for each questionnaire.  
Although the PPS patients selected for our study had elevated levels of fatigue, the 
scores for fatigue measured with the FSS, the NHP energy category, and the PPL 
fatigue item were comparable to those reported in the literature.2,6,7,9-13,36 It must be 
mentioned that most of the NHP energy category scores reported in the literature 
were calculated from weighted item scores.37 However, the importance of weighting 
is under discussion,38,39 and the median score of 33 found in our study is well within 
the range of values reported in the literature.2,11-13,36  
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Table 5 The effect of sample size on the smallest detectable change 
    
 Individual n=25 n=50 
FSS (range, 1–7) 1.5 (27%) 0.5 (9%)k 0.3 (6%) 
PPL fatigue item (range, 0–7) 2.0 (36%) 0.6 (10%) 0.4 (7%) 
SFQ (range, 1–7) 1.9 (39%) 0.6 (13%) 0.4 (9%) 
The smallest detectable change is expressed in original scale points and as a percentage of the mean 
of the 2 study visits. For an individual case, the change required will be approximately 2 SDs of the 
mean difference. For comparison of a group score in a paired situation, the smallest detectable change 
was calculated from the formula: n>k·σ2/∆2, where n=number of subjects, k=constant based on tables 
of standard normal curve (k=10.51 for α=0.05 and β=0.10), σ2=variance of differences, and ∆=smallest 
detectable change.35 
 
Validity 
Analysis of concurrent validity showed low correlations (range, .43–.68) between the 
total scores of all pairs of questionnaires, which indicate that little of the variation in 
score of one questionnaire was explained by the variation in score of another 
questionnaire. Moreover, it was found that the normalised total scores differed 
between most questionnaires. Compared with the scores of the FSS, the PPL fatigue 
item, and the SFQ, the scores of the NHP energy category were markedly lower. It is 
well known that the dichotomous items of the NHP have a high threshold for positive 
scores40-42 and are not likely to detect minor illnesses.43 Especially item 2 of the NHP 
energy category (“Everything is an effort”), which was scored affirmative by only 22% 
of the patients (table 1), showed a considerable ceiling effect.  
In contrast with the NHP energy category, the FSS and the PPL fatigue item 
seemed to have a low threshold. According to the median item values, 50% of the 
patients had a maximum score of 7 on the FSS for the items 6 (“My fatigue prevents 
sustained physical functioning”) and 8 (“Fatigue is among my three most disabling 
symptoms”). Therefore, item 2 of the NHP energy category and items 6 and 8 of the 
FSS may assess different aspects of fatigue. However, it appeared that 15 of the 17 
items on the 4 questionnaires formed an almost strongly homogeneous scale 
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(H=.49), which indicates that the questionnaires did not measure different constructs 
or other aspects of fatigue. Interestingly, the first 2 items of the FSS (“My motivation 
is lower when I am fatigued”; “Exercise brings on my fatigue”) did not fit in the overall 
scale, nor did they fit in their own 9-item FSS scale. The latter was surprising, 
because all 9 items of the FSS fit the assumption of unidimensionality when used to 
assess patients with chronic hepatitis C.24 The fitting of these items may depend on 
the study population in which the FSS was applied. However, it must be stated that 
also in chronic hepatitis C patients,24 the first 2 items of the FSS showed the lowest 
item-total correlations, which indicates that their scores reflected the total score least 
accurately.  
 
Reproducibility 
The ICCs of the FSS (.83) and the SFQ (.84) and the Spearman ρ of the PPL fatigue 
item (.80) seemed to be satisfactory. The ICC of the FSS was in accordance with 
ICCs found in other groups of patients (ICC range, .82–.86).23,24 However, the lower 
limits of the 95% CIs of the ICCs of the FSS (.72) and the SFQ (.73) found in this 
study suggest only moderate test-retest reliability.44,45 This might be due to large day-
to-day variations in fatigue in PPS patients. However, because the literature presents 
no data on the CIs of the ICCs for the FSS, the PPL fatigue item, or the SFQ in PPS 
patients, this cannot be verified. In addition, the moderate test-retest reliability of 
fatigue as an outcome measure may be inherent in its subjective character, because 
the perception of fatigue depends not only on physical but also mental and emotional 
status.46  
The Cronbach α values for internal consistency that were found for the FSS and for 
the NHP energy category were comparable to those reported in other studies.22-
24,40,47,48 With only 3 dichotomous items, the low internal consistency of the NHP 
energy category was not expected to be higher than already reported in other patient 
groups. The internal consistency of the SFQ was acceptable but lower than reported 
by Alberts et al.27  
In addition to the assessment of reproducibility at the group level, it is also 
important to determine the reproducibility of an instrument at the individual level.49 
The limits of agreement found for the FSS, the PPL fatigue item, and the SFQ were 
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wide (table 4) and may indicate large individual day-to-day variations. With a 95% CI, 
the change in score of an individual, compared with the score on the first study visit, 
had to be at least 2 points on the scale of each questionnaire to be detected. The 
smallest detectable changes for the FSS, the PPL fatigue item, and the SFQ ranged 
from 27% to 39% (table 5). Therefore, at the individual level, the FSS, the PPL fatigue 
item, and the SFQ show too much variation in score to be able to detect changes in 
fatigue.  
Although less appropriate for detecting differences within an individual, the FSS, 
the PPL fatigue item, and the SFQ may be useful for group comparisons, in which the 
smallest detectable changes are much smaller. In a sample size of 50, the FSS, the 
PPL fatigue item, and the SFQ can detect changes of less than 10% from baseline. 
Similar conclusions with respect to the ability to detect change have been reported for 
the NHP energy category.42,50  
 
CONCLUSIONS 
When comparing the severity of fatigue in PPS reported in various studies, one 
should take into account the fact that, although the FSS, NHP energy category, PPL 
fatigue item, and SFQ measure the same construct of fatigue, the severity of fatigue 
may differ considerably as a result of differences in the range for which 
questionnaires measure fatigue. The NHP energy category, in particular, appeared to 
have a high detection threshold to measure fatigue.  
The choice of the appropriate questionnaire to measure fatigue in PPS may 
depend on the expected range in the severity of fatigue and the desired 
responsiveness of the questionnaire. For instance, if one is only interested in 
identifying high levels of fatigue, the NHP energy category may be preferred. On the 
other hand, if the main interest is to identify changes in fatigue, for instance due to 
intervention, it should be realized that no differences between the FSS, the PPL 
fatigue item, and the SFQ were found for reproducibility, which was comparable for 
all questionnairesthat is, sufficient at the group level but lacking precision at the 
individual patient level. The choice may further depend on the desired simplicity of 
the instrument, that is, the number of questions. Finally, when applying the FSS to 
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measure fatigue in PPS, one should consider omitting items 1 and 2, because they 
do not appear to fit in the same fatigue construct as the other FSS items or with the 
other fatigue questionnaires studied.  
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ABSTRACT 
Objectives: To determine what changes in maximal isometric strength can be 
detected in a symptomatic quadriceps muscle in patients with postpoliomyelitis 
syndrome (PPS) and to investigate the association between the variability in maximal 
strength and maximal voluntary activation (MVA).  
Design: Repeated-measures over a 3-week interval.  
Setting: University hospital.  
Patients: Convenience sample of 65 patients with PPS.  
Intervention: Dynamometer testing.  
Main outcome measures: Maximal voluntary contraction (MVC) torque of the 
quadriceps was measured with a Kin-Com dynamometer and MVA was determined 
by twitch interpolation.  
Results: The mean difference between the 2 consecutive measurements was -0.7 
±12.8Nm (95% confidence interval [CI], -3.9 to 2.5). The test-retest reliability was 
excellent for MVC torque (intraclass correlation coefficient [ICC]=.96; 95% CI, .93–
.98) and moderate for MVA (ICC=.73; 95% CI, .56–.85). The smallest detectable 
change in MVC torque was 25% for an individual. The variability in MVA explained 
18% of the variability in maximal strength.  
Conclusions: Variability in maximal quadriceps strength, measured with a fixed 
dynamometer, was large and partly related to variability in MVA. This implies that 
even with optimally standardized strength testing, a follow-up of many years is 
required to objectify progression of quadriceps weakness in an individual patient with 
PPS. To demonstrate changes in strength in groups of patients in follow-up or 
intervention studies, feasible sample sizes are required. 
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eople who suffered from acute poliomyelitis earlier in their lives may develop 
new neuromuscular symptoms after decades of neurologic and functional 
stability. This late deterioration is referred to as postpoliomyelitis syndrome (PPS), 
and it is characterized by new or increased muscle weakness that is due to a slow, 
progressive loss of muscle fibres.1-4 
The diagnostic criteria for PPS have recently been revised, and now include the 
criterion that new symptoms should persist for at least 1 year.5 However, it is 
questionable whether an individual decline in strength can be identified over such a 
short period. Long-term studies have estimated that the decline in strength is only 1% 
to 2% per year.6,7 Therefore, highly sensitive measurements are required to 
demonstrate progression. Manual muscle testing and hand-held dynamometry have 
limitations with respect to their test-retest reliability and ability to detect change in 
muscle strength.8-11 In contrast, fixed dynamometers have shown good test-retest 
reliability when used to measure strength in several patient groups, based on 
intraclass correlation coefficients (ICCs) and the coefficients of variation.12,13 
However, data on reproducibility of measurements with a fixed dynamometer in PPS 
are scarce,14 and there are no data on the ability to detect change of strength within 
an individual. Knowledge of reproducibility is essential, not only to determine the 
ability of the instrument to detect individual changes, but also to determine sample 
sizes for intervention studies.  
 
Measurements of maximal voluntary strength make the assumption that the 
subject is able to fully activate the muscle. However, in subjects with multiple 
sclerosis and subjects with a history of polio, especially those with PPS, studies have 
shown impaired voluntary muscle activation.15-17 In healthy subjects, the test-retest 
reliability of maximal voluntary activation (MVA) of the quadriceps, using a bipolar 
twitch interpolation technique,18 was found to be good (ICC=.96).19 However, the 
reproducibility of measurements in patients with PPS has not yet been addressed.  
Variability in voluntary activation must lead to variability in voluntary strength, and 
may therefore contribute to the variability in muscle performance of symptomatic 
muscles in patients with PPS, but this relationship has not yet been investigated.  
P
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Therefore, the main objective of our study was to investigate the reproducibility of 
measurements of maximal voluntary strength and MVA of the quadriceps muscle with 
symptoms of postpoliomyelitis muscle dysfunction in patients with PPS, using a fixed 
dynamometer. The second objective was to investigate the association between 
variability in strength and voluntary activation.  
 
METHODS 
Participants 
Sixty-five patients with PPS (42 women, 23 men), according to the criteria defined by 
Halstead4,20 and colleague, participated in the study. Additional inclusion criteria for 
all patients were: (1) symptoms of postpoliomyelitis muscle dysfunction21 (ie, new 
muscle weakness, new muscle fatigue, new muscle pain, or new atrophy) in at least 1 
quadriceps muscle with a minimum strength of 30Nm; (2) age between 18 and 70 
years; and (3) no symptoms of joint pain in the hip or knee or significant neurologic or 
orthopedic disorders. Subjects’ mean age ± standard deviation (SD) was 52±8 years 
(range, 36–68 years), the mean time since the onset of polio was 49±8 years (range, 
22–66 years), and the mean time since the onset of new neuromuscular symptoms 
was 10±6 years (range, 1–30 years). If both quadriceps muscles were symptomatic, 
the quadriceps with the severest symptoms was investigated. The medical ethics 
committee of the hospital approved the study, and all patients gave their written 
informed consent.  
 
Quadriceps strength 
Strength of the quadriceps was measured with a Kin-Com dynamometera with the 
subjects seated in an upright position. The axis of the dynamometer was aligned with 
the lateral femoral condyle. Subjects held on to 2 handgrips, 1 on each side of the 
seat, and were belted into the chair with an adjustable strap around the waist for 
stabilization. The force transducer was positioned just proximal and ventral to the 
malleoli. For each subject, the height of the axis of the dynamometer, the distance 
between the midpoint of the force transducer and the axis, and the adjustments of the 
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chair were recorded. Force data were sampled at 1kHz and stored on a personal 
computer.  
Each subject performed 3 maximal isokinetic contractions (30°/s) of the quadriceps 
between 100° and 30° of knee flexion to determine the optimal angle to generate 
maximal force. The optimal knee angle was individually defined as the angle at which 
peak torque occurred (mean of 3 attempts), and was used in all measurements. After 
a 5-minute rest interval, subjects performed 6 isometric maximal voluntary 
contractions (MVCs) of the quadriceps (MVC torque), with a 2-minute rest between 
tests. MVC torque was determined as the highest peak torque of the 6 trials (figure 
1A).  
 
Maximal voluntary activation 
MVA of the quadriceps was measured during the last 3 maximal contractions, using a 
twitch interpolation technique modified from the method described by Allen et al.16  
The quadriceps muscles were stimulated percutaneously with a Digitimer constant 
current stimulator,b using 2 stimulating electrodes (one 12×12cm and one 10×10cm 
aluminum foil electrode applied on dampened absorbent sponge tissue) placed over 
the anterior thigh. Unidirectional square-wave pulses of 50µs were used at a voltage 
of 200V. The current was chosen such that, with a 1-second 30-Hz stimulation, at 
least 25% of the MVC torque was achieved.  
During an MVC, 100-Hz stimulation was applied at the time of peak torque for 
40ms. Five seconds after the first stimulation, an identical stimulation was delivered 
to the relaxed quadriceps to evoke a control tetanus. Voluntary activation was 
calculated from the increment in torque produced by stimulation at the moment of 
peak torque and the torque due to the control stimulation (figure 1B). MVA was 
determined as the highest voluntary activation of the 3 trials.  
 
Maximal voluntary strength and MVA of the quadriceps were measured twice 3 
weeks apart. The same individually determined settings of the dynamometer were 
used for both visits. 
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Data analysis 
Systematic differences between visits were analyzed by paired t tests. For each visit, 
the MVC torque was compared (paired t test) with the voluntary torque at the start of 
stimulation (MVCSTIM torque) in the MVA trial. The test-retest reliability was assessed 
by calculating the ICC and the 95% confidence interval (CI) of the ICC, using a 
random effects 1-way analysis of variance.22 A lower limit of the CI of at least .75 is 
considered to be good test-retest reliability.23,24  
To assess the smallest change that can be detected within an individual, the 95% 
limits of agreement for repeated MVC torque and MVA were analyzed according to 
the Bland and Altman method.25 For each subject, the difference between the 2 visits 
was plotted against the mean of the 2 visits. For normally distributed differences, 95% 
of the differences will lie between: mean(visit 2-visit 1)±2 SD. Because the magnitude of 
the difference in MVC torque increased with increasing mean values, the 95% limits 
of agreement were calculated after log transformation of the data as: mean(log[visit 2]-
log[visit 1])±2 SD, and expressed as ratios after taking the antilog of the resulting 
values.25  
Estimates of sample size were made for an effect study comparing 2 independent 
groups. The minimal total number of subjects needed (n) to find a significant 
difference in change of MVC torque between groups was calculated from the formula: 
n>4(Zα+Zβ)2SD2/δ2, with Z values based on tables of standard normal curves 
(Zα+Zβ=3.242 for α=.05 and β=.10), SD as the SD of the difference, and δ as the 
minimal difference in effect between groups that is considered of clinical interest.26,27  
The relationship between the difference in MVA between visits and the difference 
in MVCSTIM torque between visits was studied by calculating the Pearson correlation 
coefficient. Statistical significance was defined at the P less than .05 level. For 
statistical analysis the SPSS, version 10.0.5, software packagec was used.  
 
RESULTS 
The mean knee angle ± SD of the quadriceps to generate maximal force was 54°±11° 
of flexion (range, 30°–74°).  
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Quadriceps strength 
The mean difference in MVC torque between the 2 measurements (second minus 
first measurement) was -0.7±12.8Nm (95% CI, -3.9 to 2.5) (table 1). The test-retest 
reliability of MVC torque was excellent, according to the ICC. 
 
Table 1 Score per visit and test-retest reliability 
 
 Visit 1  
(range) 
Visit 2 
(range) 
∆ Visit 2-Visit 1 95% CI∆ ICC 95% 
CIICC 
MVC torque 
(n=65) 
87.3±43.5 
(21–199) 
86.6±45.6 
(21–213) 
-0.7±12.8 -3.9 to 2.5 .96 .93–.98 
MVA 
(n=42) 
67.3±20.1 
(13.3–97.6) 
67.1±18.9 
(28.8–98.9) 
-0.3±14.4 -4.7 to 4.2 .73 .56–.85 
MVCSTIM torque 
(n=42) 
76.4±37.8 
(23.0–170.6) 
73.0±35.9 
(24.0–175.1) 
-3.4±15.7 -8.3 to 1.5 .91 .84–.95 
Torque due to the 
control stimulation 
(n=42) 
16.6±7.4k 
(5.0–38.5) 
17.6±7.2k 
(5.4–36.0) 
k1.0±4.7k -0.4 to 2.5 .79 .64–.88 
The score on the 2 visits and the difference (∆) are presented as mean ± SD in newton meters, and 
the 95% CI of ∆ (CI∆) is given. The ICC and the 95% CI of the ICC (CIICC) are given. 
 
The distribution of the difference in MVC torque between the 2 measurements is 
shown in figure 2A. The 95% limits of agreement, expressed as ratios after log 
transformation of the data, were 0.75 and 1.29. According to these limits, the smallest 
decline in MVC torque that can be detected within an individual is 25%.  
From the 95% CI around the mean, it follows that the smallest decline in 
quadriceps strength that can be detected at group level is 3.9Nm (4.5%) (table 1). 
According to the minimal change (δ) that is considered of clinical interest, the total 
number of subjects needed in an intervention study would be greater than 
4×3.2422×12.82/δ2. For example, to demonstrate a 10% difference in the change in 
quadriceps strength between 2 groups as statistically significant, a total of 92 
subjects (2 groups of 46 subjects) would be needed.  
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Maximal voluntary activation 
MVA was determined in 42 patients. MVA could not be determined in 22 patients 
because the required 25% of maximal torque could not be reached with stimulation. 
For these subjects, either the torque-current relationship reached an early maximum, 
for example, there was no further increase in torque at higher currents (n=19), or a 
higher current was not tolerated (n=3). Data were missing for 1 subject, due to a 
recording failure. The MVC torque of the 23 patients whose MVA could not be 
determined was comparable to the MVC torque of the other 42 patients.  
The 30 Hz stimulation of the relaxed quadriceps during 1 second yielded 34%±7% 
of MVC torque on the first study visit and 36%±8% of MVC torque on the second 
study visit. MVCSTIM torque was significantly lower than MVC torque on both study 
visits (P<.01). MVCSTIM torque was 90.9%±14.8% of MVC torque on the first visit and 
90.1%±11.6% of MVC torque on the second visit.  
The test-retest reliability of MVA and the torque due to the control stimulation were 
moderate, according to the ICC (table 1). The distribution of the difference in MVA 
between visits is shown in figure 2B. The limits of agreement between the 2 MVA 
measurements were -29.0 and 28.5.  
The correlation coefficient of the difference in MVA between the 2 measurements 
and the difference in MVCSTIM torque between the 2 measurements was .42 (P<.01) 
(figure 3). Therefore, 18% (r2) of the variance in MVCSTIM torque was explained by the 
variance in MVA.  
 
DISCUSSION 
Many patients with PPS complain of progressive muscle weakness. However, the 
rate of strength loss appears to be slow, and therefore highly sensitive 
measurements are required to demonstrate a decline.  
The first objective of this study was to determine the reproducibility of MVC torque 
of symptomatic quadriceps muscles in patients with PPS, using a fixed dynamometer. 
The ICC for MVC torque measurements found in this study indicated excellent test-
retest reliability at group level, which is in accordance with the findings of other 
studies with regard to the reliability of fixed dynamometry.14,28 However, the large 
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between-subjects variance in MVC torque, due to extensive differences in the degree 
of paresis, assures a high correlation, because the ICC is determined as the ratio of 
the between-subjects variance to the between-subject variance plus error variance.22 
Figure 3 The difference in MVA between visits is plotted against the difference in 
MVCSTIM torque. The difference in MVA is calculated from the score on the second 
visit minus the score on the first visit. The difference in MVCSTIM torque is expressed 
as the percentage of change from the first visit. The squared correlation coefficient 
(r2) indicates the variance in MVCSTIM torque that is explained by the variance in 
MVA.  
 
To focus in particular on the error variance, the differences in MVC torque between 
visits were plotted against their mean.25 The limits of agreement calculated from this 
plot (0.75–1.29) were wide when compared with the smallest detectable difference 
found for isometric quadriceps strength in healthy subjects (14%).29 The limits of 
agreement were only slightly better than for hand-held dynamometry in polio 
survivors (limits of agreement, 0.76–1.52).11 This was surprising, because the 
difference in MVA
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variability due to measurement error is expected to be less for fixed than for hand-
held dynamometry because of better standardization. Apparently, the within-subject 
variability is a major determinant of the reproducibility of maximal strength 
measurements in polio subjects.  
The finding that a change of at least 25% is required to detect an individual change 
in MVC torque illustrates the lack of reproducibility at the individual level. To 
demonstrate a deterioration in quadriceps strength at the group level in the study 
sample, a mean decline of 4.5% would be required. Because the rate of strength loss 
is estimated at 1% to 2% per year,6,7 a follow-up of several years would be needed to 
demonstrate a decline. In fact, studies6,7,30 that have reported a significant decline in 
maximal strength all had follow-up durations of at least 4 years. The negative 
outcomes in studies with a follow-up of less than 4 years and/or small sample sizes 
may have been due to a lack of power.31-33  
Another consequence of reproducibility is that it determines the minimum number 
of subjects required for randomised controlled trials. Despite the poor reproducibility 
at the individual level, feasible sample sizes are needed to demonstrate a relevant 
improvement in studies comparing 2 independent groups.  
One factor that may account for the variability of repeated MVC torque is variability 
in voluntary activation. Unfortunately, activation levels could only be determined in 42 
patients, mainly because it was often impossible to stimulate sufficient muscle mass. 
This might be caused by the presence of subcutaneous and intramuscular fat tissue 
originating from denervated muscle fibres.34,35  
 
The MVA scores in our study were low, compared with those reported for the elbow 
flexor muscles in patients with PPS.16,33 In addition to intermuscle differences in MVA 
between the quadriceps and biceps,36 it seems likely that the lower strength values 
obtained in the trials in which stimulation was applied, compared with the values 
obtained in the trials without stimulation, have played a role. This has also been 
observed by Yue et al.37 Awareness of the forthcoming electric stimulation may have 
prevented subjects from producing maximal exertions. However, it may also be that 
the ability to exert maximal voluntary strength declined during the measurements, 
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due to increasing fatigue, especially because all muscles investigated showed 
symptoms of postpoliomyelitis muscle dysfunction.  
The reliability of MVA was moderate: the ICC (.73) was lower than that reported for 
quadriceps muscles of healthy subjects (ICC range, .86–.96).19,38 Only 18% of the 
variability in MVCSTIM torque was explained by the variability in MVA. This is not 
consistent with the assumption of the twitch interpolation technique that voluntary 
activation and voluntary force are strongly correlated. The limited contribution of MVA 
to the variability in maximal voluntary strength may be due to the curvilinear 
relationship between relative force (force as a percentage of the maximal “true” force) 
and voluntary activation.19,39-41 This implies that the variability in voluntary activation 
is not linearly related to the variability in voluntary force in a healthy muscle. 
However, it is unknown whether the curvilinear relationship between relative force 
and voluntary activation is similar for healthy and symptomatic muscles. Furthermore, 
in our study the knee angle was individually adjusted to optimal muscle length, and 
therefore differed between subjects. There are indications that the force-activation 
relationship is influenced by muscle length.39,42  
Another reason for the relatively small contribution of the MVA variability to the 
variability in maximal voluntary strength may be the possibility of coactivation of the 
hamstring muscles, which was not measured. Antagonistic coactivation decreases 
the voluntary extension torque output on the dynamometer, but has no effect on the 
MVA. It has been reported that, during maximal isometric knee extension, subjects 
demonstrate significant antagonistic coactivation (20%–40% depending on age).43,44  
 
CONCLUSIONS 
Even in optimal standardized conditions, strength measurements made with a fixed 
dynamometer are unable to detect small changes in the strength of symptomatic 
quadriceps muscles in individual patients with PPS. However, the reproducibility is 
sufficient to evaluate changes in groups of subjects in both follow-up and intervention 
studies.  
The variability in maximal strength was related to the variability in MVA, although 
only to a limited extent. Several factors may have influenced the findings, and further 
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research should be carried out, for instance, to determine the relationship between 
voluntary activation and contraction torque as a function of muscle length and to 
assess the level and variability of antagonistic coactivation. This may improve our 
understanding of the variability in maximal strength of patients with PPS.  
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ABSTRACT 
Objective: To assess the reproducibility of walking performance, heart rate, and 
perceived exertion at self-preferred speed and maximal walking speed in patients 
with the postpoliomyelitis syndrome (PPS).  
Design: Repeated measurement at a 3-week interval.  
Setting: University hospital.  
Participants: Convenience sample of 65 patients with PPS.  
Interventions: Not applicable.  
Main outcome measures: Walking performance: the distance walked in 2 minutes at 
a self-preferred speed and the time needed to walk 75m at maximal speed, heart 
rate, and rating of perceived exertion (RPE) on an 11-point scale.  
Results: Test-retest reliability of walking performance was excellent for both tests 
(intraclass correlation coefficient [ICC] range, .94–.97). No systematic differences 
existed between test and retest. The smallest detectable change for an individual was 
15% for both tests. Test-retest reliability for heart rate was good (ICC=.86) but 
moderate for RPE (Spearman ρ range, .67–.70). The smallest detectable change for 
RPE was between 4 and 6 scale points. The variability in walking performance was 
significantly correlated with the variability in heart rate at self-preferred speed (r=.36, 
P<.01) but not with the variability in RPE (r=.20, P=.11).  
Conclusions: Both walking tests showed good reproducibility and may be appropriate 
to monitor (individual) changes in walking capacity in patients with PPS. Because of 
its moderate reproducibility, RPE does not seem to be suitable to monitor physical 
exertion. The usefulness of an objective measure such as heart rate for this purpose 
needs further investigation.  
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ncreased difficulty with walking is among the major functional problems persons 
with the postpoliomyelitis syndrome (PPS) experience.1-4 In particular, the 
decrease in ability to walk outdoors is perceived as a major problem by patients with 
PPS5 and may affect their level of independence and life satisfaction.6  
In cross-sectional studies of patients with PPS, walking performance has been 
measured in a laboratory setting for both self-preferred speed and maximal speed.5,7,8 
Whether such tests are appropriate in longitudinal studies, for instance to determine a 
decline in walking capacity, depends largely on their reproducibility. Although the 
reproducibility of walking tests at self-preferred and maximal speed is good in 
patients with respiratory disease,9 chronic heart failure,10 and neurologic 
impairment,11 no data on the reproducibility of the tests are available in patients with 
PPS.  
In addition to walking performance, it may also be relevant to assess physical 
effort, which relates to the length of time that the activity can be sustained. Physical 
effort can be measured objectively by recording the heart rate, but also at the level of 
perception, by rating the perceived exertion (RPE). The RPE has been used to 
determine exercise levels in PPS patients.12 Recently, the March of Dimes Birth 
Defects Foundation recommended use of an RPE scale13 for daily life activities to 
avoid excessive fatigue in patients with PPS.14 Whether an RPE scale is appropriate 
for this purpose depends on its stability across measurements and on its relation with 
the actual effort and performance. Unfortunately, no information exists regarding the 
reproducibility of the RPE in PPS patients. Further, the literature has revealed 
inconsistencies about the strength of the relation between the RPE and physiologic 
criterion measures, such as heart rate.15,16 Knowledge of the reproducibility of RPE 
and its relation to walking performance and heart rate during walking, may provide 
supportive evidence for its use to avoid overloading in patients with PPS.  
 
The objective of the present study was to determine the test-retest reproducibility of 2 
walking tests with respect to performance and physical effort in patients with PPS. 
One test measured the distance covered in 2 minutes when walking at a self-
preferred speed, and the other test measured the time needed to walk 75m as fast as 
possible. We also investigated associations between the variability in performance 
I 
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and the variability in physical effort, measured by means of heart rate (only at self-
preferred speed) and RPE.  
 
METHODS 
Participants 
Sixty-five subjects with PPS, according to the criteria defined by Halstead,17,18 
participated in the study. Inclusion criteria were (1) symptoms of postpoliomyelitis 
muscle dysfunction19 (ie, new muscle weakness, new muscle fatigue, new muscle 
pain, or new atrophy) in at least 1 quadriceps, (2) ability to walk for at least 2 minutes, 
(3) age between 18 and 70 years, and (4) no significant other neurologic disorders. 
Use of walking aids and orthotic and orthopedic devices was allowed. The Medical 
Ethics Committee of the hospital approved the study, and all subjects gave written 
informed consent.  
 
Protocol 
Two walking tests were performed on 2 visits that were separated by a 3-week 
interval. The tests were performed on a closed, marked, 65-m indoor trajectory and 
were started after the subjects had been sitting on a chair to rest for 5 minutes.  
First, subjects walked at a self-preferred walking speed for 2 minutes, and the 
walking distance was measured. Then, after a 5-minute rest interval, they walked at 
their maximal walking speed (without running) over a distance of 75m, and the time 
needed to walk that distance was measured with a stopwatch. They were allowed to 
use walking aids and devices during the tests as they would when walking outdoors. 
Heart rate was recorded in both tests. After each walking test, the subjects rated their 
perceived exertion (RPE) on an 11-point scale deduced from Borg,13 ranging from 0 
(no exertion) to 10 (maximal exertion). The measurements on the second visit were 
scheduled at the same time of day as those on the first visit, and subjects walked with 
the same walking aids and devices on both visits.  
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Data analysis 
The heart rate during walking at self-preferred speed showed a steady state after 60 
seconds. Therefore, the mean heart rate between 70 and 100 seconds was 
calculated and used in the analysis. No heart rate was analyzed for the test at 
maximal speed because no steady state could be observed.  
The test-retest reliability for walking distance, walking time, and heart rate was 
assessed by the intraclass correlation coefficient (ICC) and the 95% confidence 
interval (CI) of the ICC, by using a random effects 1-way analysis of variance.20 A 
lower limit of the CI of at least .75 is considered as good test-retest reliability.21,22 The 
test-retest reliability of RPE was analyzed by calculating the Spearman correlation 
coefficient.  
Systematic differences between visits were tested with the Student t tests for 
walking distance, walking time, and heart rate, and with the Wilcoxon signed-rank test 
for RPE. For walking performance and heart rate, agreement of measurements was 
analyzed according to the Bland-Altman method.23 The 95% limits of agreement 
(LOA) were calculated as mean (visit 2-visit 1)±2 standard deviations (SDs) to 
determine the smallest change that can be detected within an individual. For the 
RPE, agreement of measurements was analyzed by calculating the 2.5 and 97.5 
percentiles of the difference between the 2 visits.  
Associations between walking performance, RPE, and heart rate were determined 
with respect to differences between visits by calculating the Pearson correlation 
coefficients. Statistical significance was defined at the P less than .05 level. For 
statistical analysis SPSS, version 10.0.5,a was used.  
 
RESULTS 
Sixty-three subjects (40 women, 23 men) completed the walking tests on both study 
visits. Heart rate data on 3 subjects were missing because of recording failures.  
The mean age of the subjects was 52±7 years. The mean time since the onset of 
polio was 49±8 years, and the mean time since the onset of symptoms of 
postpoliomyelitis muscle dysfunction was 10±6 years. Thirty-three patients (52%) 
wore orthopedic footwear, 14 patients (22%) walked with an ankle-foot or knee-ankle-
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foot orthosis, and 9 patients (14%) used a cane or crutches. Nineteen patients (30%) 
did not use any orthopedic devices or walking aids.  
 
Walking at self-preferred speed 
According to the ICCs, test-retest reliability was excellent for walking distance and 
good for heart rate (table 1). Test-retest reliability for RPE was satisfactory (r=.67, 
P<.01). The mean level of perceived exertion corresponded to “light exertion” (score, 
3). There were no systematic differences between visits in walking distance, heart 
rate, or RPE.  
 
Table 1. Results for walking at self-preferred speed  
 
Outcomes Visit 1 Visit 2 đ* 95% CIđ 
and P 
95% LOA ICC 95% CIICC
Walking 
distance (m) 
119.2±23.9 
(52.5–158.8) 
120.2±23.9 
(60.0–166.1) 
1.0±8.5 -1.2, 3.1; 
.38 
-16.1, 18.0 .94 .90−.96 
Heart rate 
(n=60) 
102±16 
(77–144) 
100±13 
(74–137) 
-2±8` -4, 0; 
.06 
-18, 14 .86 .77−.91 
        
Outcomes Visit 1† Visit 2† dmedian
‡ P ║ 95% LOA¶ r**  
Perceived 
exertion 
2 (1, 5) 
(0–9) 
2 (1, 5) 
(0–10) 
0 (-1, 1) .45 -5, 4 .67  
Values are mean ± SD (range) unless otherwise noted. 
* Mean difference (đ) between visits (second visit minus first visit). 
† Median, 25th and 75th percentile, and range. 
‡ Median difference (dmedian) between visits with 25th and 75th percentile.
 
║ Wilcoxon signed-rank test. 
¶ 2.5th and 97.5th percentile of the difference. 
** Spearman correlation coefficient.  
 
The mean of the 2 visits against the difference between the 2 visits for walking 
distance are plotted in figure 1A. The LOA represent the smallest change that can be 
detected within an individual.  
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For walking distance, the LOA were -16.1 (-13.5% of change from the mean) and 
18.0m (15.1%); for heart rate, -18 and 14; and for RPE, -5 and 4 scale points (see 
table 1).  
No significant correlation was found between the difference in walking distance at 
the 2 visits and the difference in RPE (r=.20, P=.11). A weak relation was found 
between the difference in walking distance and the difference in heart rate (r=.36, 
P<.01). The difference in heart rate did not correlate with the difference in RPE 
(r=.14, P=.30).  
 
Walking at maximal speed 
The test-retest reliability for walking time and RPE was comparable to that for walking 
at self-preferred speed (table 2). The level of perceived effort corresponded to “more 
than average exertion” (score, 6). No systematic differences existed between the 2 
visits.  
 
Table 2 Results for walking at maximal speed  
 
Outcomes Visit 1 Visit 2 đ* 95% CIđ 
and P 
95% LOA ICC 95% CIICC
Walking time (s) 60.5±20.0 
(38.2–167.4) 
60.7±18.2 
(41.4–145.6)
0.2±4.5 -1.0, 1.3; 
.77 
-8.9, 9.2 .97 .96–.98 
        
Outcomes Visit 1† Visit 2† dmedian
‡ P ║ 95% LOA¶ r**  
Perceived 
exertion 
7 (4, 8) 
(0–10) 
6 (4, 8) 
(0–10) 
0 (-1, 0) .14 -6, 5 .70  
See note to table 1. 
 
Because there was no particular reason for the outlier that appeared on the scatter 
plot for walking time (see figure 1B), we included the data of this subject in the 
analysis. The LOA were -8.9 (-14.6% change from mean) and 9.2 seconds (15.2%) 
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for walking time and -6 and 5 for RPE (see table 2). No correlation was found 
between the difference in walking time and the difference in RPE (r=.01, P=.97).  
 
DISCUSSION 
The results showed that the test-retest reliability of walking performance and heart 
rate was good. The ICCs for walking performance in the present study were 
comparable to those reported for other populations.11,24,25 In contrast to the findings of 
several other studies on reproducibility of walking performance,26-28 no learning 
effects were found. Further, the smallest detectable change in walking performance 
at individual level was better than that obtained by strength measurements using a 
handheld dynamometer (smallest detectable changes of ≥24%).29 Compared with 
such strength measurements, the walking tests in the present study will detect 
deterioration in performance more readily and are, therefore, appropriate for 
comparing conditions at the individual and at the group levels.  
It appeared that the smallest detectable change in walking performance was equal 
for self-preferred and maximal speed. We expected that walking at maximal speed 
would be less reproducible because it may be more susceptible to differences in 
motivation,10 and patients may not be used to performing activities at maximal speed. 
On the other hand, variability in maximal walking speed may have been limited by the 
use of walking aids and orthotic devices and by certain limitations in joint mobility.  
Although the reproducibility of walking performance and heart rate were good in 
the present study, the reproducibility of RPE was moderate. The wide LOA indicate 
that the individual effort that is perceived during a similar performance under the 
same circumstances varies considerably. Similar findings have been reported for 
healthy subjects.30,31 Although one might expect the reproducibility of RPE to benefit 
from practice,32,33 RPE does not seem to be a reliable measure of physical exertion in 
walking tests in patients with PPS. Although RPE correlates with local muscle 
fatigue,34 its poor reproducibility in walking tests may result from variation in factors 
other than local muscle fatigue (eg, emotional state).35  
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To investigate whether the variability of walking performance was related to the 
variability in heart rate and the variability in RPE, correlations were calculated. As 
expected, an increase in walking performance was associated with an increase in 
heart rate. However, a change in walking performance did not correlate with a change 
in RPE. A reason for this finding may be that limited variation in walking speed is not 
likely to result in differences in perceived exertion.  
A limitation of the analysis of the associations among performance, heart rate, and 
RPE is that only a part of a full relationship could be investigated. Preferably, these 
variables should be compared over larger scale ranges by measuring heart rate and 
RPE at predetermined intervals of walking speed.36  
 
CONCLUSIONS 
Reproducibility of walking at different speeds was good in patients with PPS. 
Therefore, both walking tests are appropriate to monitor walking performance over 
time. Because no difference existed in reproducibility between the tests at different 
speeds, the choice of test must be based on other criteria. Testing at maximal speed 
might be more sensitive because one may assume that a strength decline in the 
muscles that are responsible for locomotion will affect walking performance at 
maximal speed more readily than at self-preferred speed. On the other hand, if the 
interest is primarily to study changes in actual walking performance, it might be 
preferable to use the walking test at self-preferred speed because it conforms more to 
the normal daily situation.  
From the moderate reproducibility of RPE at the individual level, we conclude that 
this is not an appropriate tool to monitor the physical performance of patients with 
PPS to avoid overload of their physical capacity. Heart rate was a better indicator of 
physical effort. However, the appropriateness of heart rate as a way to monitor 
physical effort in patients with PPS must be determined in further studies.  
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ABSTRACT 
Objectives: To investigate the effect of pyridostigmine on fatigue, physical 
performance, and muscle function in subjects with postpoliomyelitis syndrome. 
Methods: 67 subjects with increased fatigue and new weakness in one quadriceps 
muscle showing neuromuscular transmission defects, were included in a randomised, 
double blind, placebo controlled trial of 60 mg pyridostigmine four times a day for 14 
weeks. Primary outcome was fatigue (on the ‘‘energy’’ category of the Nottingham 
Health Profile). Secondary outcomes included two-minute walking distance and 
quadriceps strength and jitter. Motor unit size of the quadriceps was studied as a 
potential effect modifier. The primary data analysis compared the changes from 
baseline in the outcomes in the last week of treatment between groups. 
Results: 31 subjects treated with pyridostigmine and 31 subjects treated with placebo 
completed the trial. No significant effect of pyridostigmine was found on fatigue. The 
walking distance improved more in the pyridostigmine group than in the placebo 
group (by 7.2m (6.0%); P<0.01). Sub-group analysis showed that a significant 
improvement in walking performance was only found in subjects with normal sized 
motor units. Quadriceps strength improved more in the pyridostigmine group than in 
the placebo group (by 6.7Nm (7.2%); P=0.15). No effect of pyridostigmine was found 
on jitter. 
Conclusions: Pyridostigmine in the prescribed dose did not reduce fatigue in subjects 
with postpoliomyelitis syndrome. However, it may have a limited beneficial effect on 
physical performance, especially in subjects with neuromuscular transmission defects 
in normal sized motor units. 
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ubjects with postpoliomyelitis syndrome1 often complain of fatigue2-4 and a 
deterioration in functional abilities.5-7 These symptoms may, in part, reflect 
neuromuscular transmission defects.8-11 The hypothesis in postpoliomyelitis 
syndrome is that the enlarged motor units which were formed during the recovery 
phase lose their ability to maintain all their sprouts, which slowly deteriorate.12 This 
deterioration may be accompanied by increasing neuromuscular transmission defects 
as a result of progressive dysfunction of acetylcholine synthesis and release.12-14 The 
severity of these transmission defects might increase with increasing motor unit 
size.15 Furthermore, polio patients, especially those with postpoliomyelitis syndrome, 
are often unable to activate their muscles fully, which may be related to 
neuromuscular transmission defects.16  
Pyridostigmine, an anticholinesterase inhibitor, prolongs the effectiveness of 
acetylcholine. In open studies of pyridostigmine in patients with postpoliomyelitis 
syndrome, both neuromuscular transmission defects and perceived fatigue 
decreased.8,17,18 However, a randomised double blind trial failed to confirm a 
beneficial effect.19 In that study, patients were not selected on the basis of a 
predefined level of fatigue or on the presence of neuromuscular transmission defects, 
and the responsiveness of the primary outcome measure, the short form 36 item 
questionnaire (SF-36), may have been insufficient to detect change.20-22 Furthermore, 
the investigators questioned the adequacy of 180 mg of pyridostigmine a day.19  
 
The present placebo controlled double blind trial was undertaken to study the effect 
of 240 mg pyridostigmine a day in a selected group of subjects with postpoliomyelitis 
syndrome who had an increased level of fatigue and proven neuromuscular 
transmission defects in a symptomatic quadriceps musclea muscle that is 
functionally important for locomotion. Our primary aim was to investigate the effect of 
pyridostigmine on perceived fatigue. Secondary objectives were to investigate the 
effects on physical performance and muscle function.  
 
S 
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METHODS 
Patient selection and baseline assessment 
Ambulatory subjects with postpoliomyelitis syndrome were included if they had the 
following: 
• a fatigue score of 10 points or more on the short fatigue questionnaire23 
• symptoms of postpoliomyelitis muscle dysfunction24 in at least one quadriceps 
muscle 
• neuromuscular transmission defects (mean jitter >30µs or more than two jitter 
values of >40µs) in the symptomatic quadriceps muscle on single fibre 
electromyographic stimulation (S-SFEMG)25,26 
• a minimum quadriceps strength of 30Nm 
• age between 18 and 70 years 
Exclusion criteria were significant neurological, orthopaedic, cardiovascular, 
pulmonary, or endocrine disorders, and anaemia or thyroid dysfunction, both checked 
by blood tests. The quadriceps with the severest symptoms was investigated.  
The duration of symptoms of postpoliomyelitis syndrome, the severity of paresis of 
the legs, and motor unit size of the lateral vastus were recorded at baseline. The 
severity of paresis was calculated as a sum score of 16 lower extremity muscle 
groups,4 based on manual muscle testing.27 The size of at least 10 motor units was 
estimated from multichannel surface EMG recordings.28 Enlarged mean motor unit 
size was defined as >4 mV·ms.28  
The medical ethics committees of the hospitals involved approved the study. All 
subjects gave their written informed consent. 
 
Randomisation, blinding, and treatment regimen 
Randomisation of treatment allocation was done in blocks of four. All treatment 
allocations were concealed for the patients as well as the researchers. The data 
analyst remained blinded until after the primary outcome analyses.  
 A dose of 60 mg pyridostigmine four times a day was given for 14 weeks. The 
dose was gradually increased during the first six days from 4x10 mg to 4x60 mg, to 
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reduce the chance of adverse effects. From the fourth day onwards, 0.125 mg 
atropine was added at each dose to mask the parasympathetic effects of 
pyridostigmine. The placebo-treated subjects also received pyridostigmine during the 
first three days in the same incremental dose to improve blinding. Subsequently, the 
pyridostigmine was phased out in two days, and from day 6 onwards placebo 
pyridostigmine was given. From day 4 onwards this was combined with placebo 
atropine. Drug treatment was taken 1.5 to 2 hours before each study visit. 
Compliance was checked by counting the remaining pills. 
 
Study design 
Subjects were measured five times: two baseline visits, with a three week interval to 
check for learning effects, a visit in the fifth and the 14th week of treatment to 
evaluate acute and chronic effects, and a visit three weeks after cessation of 
treatment. For each subject, all visits were scheduled at the same time of day. The 
drug treatment started two weeks after the second baseline visit (range one to three). 
 
Outcome measures 
Primary outcome was the energy category of the Nottingham Health Profile (NHP).29 
Unweighted sum scores ranged from 0 (no complaints) to 100 (answered yes to all 
questions). Secondary outcomes included questionnaires and measurements of 
physical performance and muscle function. 
 
Questionnaires 
The following questionnaires were used: 
• The fatigue severity scale (FSS), with a score ranging from 1 (no effect of fatigue 
on daily life) to 7 (severe, disabling fatigue).30 
• The subjective benefit of the treatment,31 with two questions: (1) ‘‘What, in your 
opinion, is the effect of the treatment?’’, with answers ranging from 1: ‘‘very much 
worse’’, to 7: ‘‘very much improved’’; and (2) ‘‘Compared to the period before 
treatment, your fatigue complaints have …?’’, with answers ranging from 1: 
‘‘greatly increased’’, to 7: ‘‘greatly decreased’’. A score of 4 indicated no change. 
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Physical performance 
Physical performance was assessed in the following ways: 
• The distance walked in two minutes at comfortable speed, and maximal walking 
performancethe time needed to walk 75m as fast as possible.  
• The duration of walking in the daily environment, measured with an ambulatory 
activity monitor.32 The sum of walking activities (that is, continuous walking for at 
least five seconds) in a 48 hour recording was expressed as the percentage of the 
total recording time. Walking duration was measured at baseline and in the last 
week of the drug treatment in 24 consecutively enrolled subjects (10 
pyridostigmine, 14 placebo). 
 
Muscle function 
Muscle function was determined as follows: 
• Maximal quadriceps strength on a chair dynamometer.a Subjects undertook three 
isometric maximal voluntary contractions (MVC) at an optimal knee angle with a 
two-minute rest interval; the greatest contraction was included in the analysis. 
• Maximal voluntary activation (MVA) of the quadriceps, determined by interpolated 
stimulation.16 Unidirectional square wave pulses of 50ms were used at a voltage 
of 200V.b The current was chosen such that with a 1s stimulation of 30 Hz, at least 
25% of the MVC was reached. The quadriceps was stimulated for 40ms at 100 Hz 
at peak force during an MVC and five seconds later at rest (control tetanus). MVA 
was calculated from the increment in force produced by stimulation during the 
MVC (a) and the force due to control stimulation (b) as (1-a/b)x100. The highest 
MVA of three attempts was used for the analysis.  
• Muscle fatigability of the lateral vastus, determined with surface EMG during a 30s 
sustained isometric contraction at 40% of the MVC that was obtained at the first 
baseline visit.33 Muscle fatigability was quantified as the difference in the median 
frequency (MF) between the first five and the last five seconds (MF0-5s-MF25-30s). 
• Neuromuscular transmission defects (jitter) of the lateral vastus measured with 
single fibre electromyographic stimulation (S-SFEMG).34 Measurements were 
done in the week of the second baseline visit and in the 14th week of the 
treatment period. The mean consecutive latency difference (MCD) was calculated 
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for 20 different muscle fibres.35 Jitter was calculated as the mean MCD of the 
measured muscle fibres. 
 
Sample size and statistical analysis 
With a power of 90% and a significance level of 0.05, 50 subjects would be needed to 
show a one item improvement on the NHP energy category.4 Taking potential dropout 
into account, the sample size was set at 64. The primary analysis compared the 
subjects receiving pyridostigmine and the subjects receiving placebo with regard to 
changes in the outcome measures in the 14th week of treatment from the values 
obtained at the second baseline visit (t tests). The secondary analysis compared 
changes from baseline in the outcomes in the fifth week of treatment and three weeks 
after cessation of treatment between groups. The minimum clinical relevant 
improvement in the secondary outcome measures was set at 10%. The analyses 
were based on an intention to treat approach. Sub-group analyses were done for 
motor unit size (enlarged and normal), and for walking distance and quadriceps 
strength, for which sub-groups were formed on the basis of the median baseline 
value. All tests were two sided, and statistical significance was set at P<0.05. 
 
RESULTS 
Sixty seven of the 101 subjects who were screened were included (figure 1). The two 
groups were comparable with respect to demographic and baseline characteristics 
(table 1). Two subjects were excluded after treatment allocation because of thyroid 
dysfunction and anaemia. Two subjects withdrew from the study, one 
(pyridostigmine) after four weeks of treatment because of personal circumstances, 
and one (placebo) after six weeks of treatment because of dissatisfaction with the 
procedures. In general, the treatment was well tolerated. One subject 
(pyridostigmine) discontinued the drug because of severe diarrhoea, and was lost to 
follow-up for personal reasons. 
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Table 1 Baseline characteristics according to treatment group 
 
Characteristics / outcome measures 
 
Pyridostigmine 
(n=33) 
Placebo 
(n=32) 
P Value
Age (years) 51±8 52±8 0.61 
Gender (M/F ) 10/23 13/19 0.38 
Age at polio onset (years) 3.4±4.3 2.5±2.5 0.31 
Duration of PPS symptoms (years) 10.0±5.9 10.7±6.3 0.64 
Severity of paresis of the legs (range 0–32) 24±5 22±6 0.14 
Motor unit size (mV·ms) 3.7±2.4¶ 3.9±2.5** 0.75 
Short Fatigue Questionnaire (range 1–7) 5.0±1.4 4.8±1.2 0.63 
Nottingham Health Profile, energy category 
(range 0–100) 
47±34 47±36 0.95 
Fatigue Severity Scale (range 1–7) 5.6±0.8 5.8±1.0 0.38 
Two-minute walking distance, comfortable 
speed (m) 
122±21 117±27 0.37 
Maximal walking performance, 75m (s) 58±14 64±22†† 0.22 
Walking duration (percentage of total time) 6.5±2.9* 7.0±2.7† 0.70 
Quadriceps strength (Nm) 90±43 82±48 0.51 
Maximal voluntary activation (range 0–100) 70±17§ 69±22‡ 0.94 
Muscle fatigability on surface EMG 
(MF0-5s-MF25-30s) 
1.3±2.2¶ 2.3±3.0** 0.17 
Neuromuscular transmission, jitter (µs) 40±13 40±14 0.90 
With the exception of gender, values are presented as mean ± SD. Differences between the two 
groups were tested by t  tests (χ2 for gender). 
*n=9; †n=12; ‡n=23; §n=28; ¶n=29; **n=30; ††n=31 
 
Compliance and blinding 
Compliance was good. Fifty five of the 62 subjects who completed the study took at 
least 90% of their drug dose. Only two subjects (placebo) took less than 80% of their 
dose. The blinding code was not broken during the trial, and the blinding was 
successful68% of the subjects receiving pyridostigmine and 47% of the subjects 
receiving placebo guessed their actual treatment correctly (P=0.37). The investigator 
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guessed correctly for 39% of the pyridostigmine-treated subjects and for 42% of the 
placebo-treated subjects (P=0.20). 
 
Outcome 
There was no significant difference in change on the primary outcome NHP energy 
category between the two groups during the treatment period (table 2). In the 14th 
week of treatment, a significant reduction of 36% was found in both groups. No 
difference in change on the FSS or in the subjective benefit of the treatment was 
found between the two groups; both improved significantly during the treatment 
period.  
In the 14th week of treatment, the walking distance improved more in the 
pyridostigmine group than in the placebo group (by 7.2m (6.0%); P=0.003). No effect 
of pyridostigmine was found on maximal walking performance. Three weeks after the 
treatment period the pyridostigmine group improved significantly more than the 
placebo group on walking distance and maximal walking performance. No difference 
in change in the duration of walking was found between the two groups. Walking 
duration increased significantly in the pyridostigmine group.  
There was no difference in change in quadriceps strength between the two groups. 
In the 14th week of treatment, significant improvements were found in both groups. In 
the last week of treatment, 58% of the subjects in the pyridostigmine group improved 
on both quadriceps strength and walking distance, whereas 13% of the subjects in 
this group did not improve on either of these outcome measures (P<0.05, χ 2 test). In 
the placebo group, 32% improved on both outcome measures, whereas 19% did not 
(P=1.00). 
In 24 subjects (10 pyridostigmine, 14 placebo), MVA could not be measured owing 
to inability to stimulate the quadriceps to exert at least 25% of the MVC (n=21) or 
because of intolerance of the measurement (n=3). In the fifth week of treatment and 
three weeks after the treatment period, MVA had improved significantly more in the 
pyridostigmine group than in the placebo group. 
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Figure 1 Flow diagram. The number of subjects measured at the study visits during 
the trial and the compliance with the study drug in the two groups. 
101 Subjects 
evaluated  
67 Subjects 
randomised 
34 Subjects allocated to 
pyridostigmine 
33 Subjects allocated to 
placebo 
31 Subjects completed trial 
 
Compliance 
29/31 (94%) used 90-100% of medication 
2/31 (6%) used 80-90% of medication 
31 Subjects completed trial 
 
Compliance 
26/31 (84%) used 90-100% of medication 
3/31 (10%) used 80-90% of medication 
2/31 (6%) used 70-80% of medication 
31 Subjects included in outcome 
analysis 
31 Subjects included in outcome 
analysis 
Excluded 
• No neuromuscular transmission 
defects (13) or S-SFEMG failed (4) 
• Strength of the symptomatic 
quadriceps <30Nm (6) 
• Other medical conditions (11) 
Follow-up 
• 5 weeks, n=32 
1 excluded, thyroid dysfunction 
1 lost to follow-up 
• 14 weeks, n=31 
1 adverse event, lost to follow-up 
• 17 weeks, n=31 
Follow-up 
• 5 weeks, n=32 
1 excluded, anaemia 
• 14 weeks, n=31 
1 lost to follow-up 
• 17 weeks, n=31 
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Data on muscle fatigability were missing for seven subjects in both the pyridostigmine 
and the placebo groups owing to recording artefacts. Muscle fatigability did not 
change in either group. 
Jitter values were missing for three subjects in the placebo group (intolerance in 
two, technical failure in one) in the last week of treatment. No difference in change in 
jitter was found between the two groups. 
 
Sub-group analyses 
Motor unit size was missing in four subjects (three pyridostigmine, one placebo) 
owing to technical failures. Motor unit size was increased in 23 subjects (12 
pyridostigmine, 11 placebo) and was normal in 35 subjects (16 pyridostigmine, 19 
placebo). For the subjects with enlarged motor units, no difference in change 
between the two groups was found for any outcome measure. For the subjects with 
normal sized motor units, walking distance improved 9.5m more (8.4%; P=0.002), 
and maximal walking performance 2.9s more (4.5%; P=0.03) in the pyridostigmine 
group than in the placebo group. No differences in effects were found for sub-groups 
based on walking distance or quadriceps strength. 
 
DISCUSSION 
Our study provided no evidence of any benefit of pyridostigmine in reducing fatigue in 
patients with postpoliomyelitis syndrome with increased fatigue and neuromuscular 
transmission defects in a quadriceps muscle with new neuromuscular symptoms. The 
only significant difference in change between the two study groups in the 14th week 
of treatment was for walking distance, though the improvement of 6% was less than 
considered clinically relevant. 
The main question to be answered is whether pyridostigmine is indeed ineffective 
as a treatment for postpoliomyelitis syndrome, or whether the negative result reflects 
shortcomings of the study. 
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Was the dose of pyridostigmine adequate? 
Taking into account the negative result of a randomised controlled trial with 180 mg a 
day,19 we increased the dose of pyridostigmine to 240 mg. To assess whether this 
dose was pharmacologically effective, changes in neuromuscular transmission 
defects were monitored (S-SFEMG). The fact that no significant improvement in 
neuromuscular transmission was found in the pyridostigmine group might suggest 
that the dose of 240 mg was not adequate. However, the large standard deviation of 
the difference in jitter found in the placebo group (table 2), probably caused by large 
variation in neuromuscular transmission defects between end-plates, indicates that 
the reproducibility of jitter was poor. Thus jitter was not an appropriate measure to 
establish the effectiveness of the pyridostigmine dose. Nonetheless, plasma 
concentrations of pyridostigmine can vary greatly between individuals,36 and the dose 
may have been insufficient for an unknown number of subjects. This implies that 
individual adjustment may be required to obtain an effective dose. 
 
Was the ability to detect an effect of pyridostigmine adequate? 
The sample size of the study population was calculated with an expected standard 
deviation of 30 in the change in NHP energy category score.4 The NHP energy 
category scores which were obtained were in agreement with this assumption and 
confirmed an adequate power calculation. However, the NHP energy category 
showed a substantial ceiling effect at baseline, where 15 subjects (23%) had a score 
of 0. In addition, the NHP energy category scores in the placebo group decreased 
significantly during the treatment period. To demonstrate a beneficial effect of 
pyridostigmine, the scores in the pyridostigmine group would have to decrease by 
more than 33%, which was only found possible in 15 subjects.  
Fatigue was also measured with the FSS, which has more response choices and 
showed no ceiling effect. As the FSS also failed to improve with pyridostigmine, the 
lack of effect on the NHP energy category cannot be attributed to an insufficient 
ability to detect change. 
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Does pyridostigmine have an effect on muscle function? 
In this study, many comparisons were made and statistically tested. By chance, 
multiple testing can yield significant differences that do not reflect true differences 
and may produce misleading results.37 Some of the significant differences foundfor 
instance, on maximal walking performance and MVA three weeks after 
treatmentmay therefore be coincidental. However, if these differences had resulted 
from chance alone, they would have been equally distributed over the two treatment 
groups. The significant improvements in walking distance, the duration of walking, 
quadriceps strength, and MVA were all in favour of the pyridostigmine group. These 
findings suggest that pyridostigmine does improve muscle function to some extent. 
This is also supported by the significant association between the improvement in 
walking performance and the improvement in quadriceps strength, which was found 
in the pyridostigmine group but not in the placebo group.  
 It was expected that pyridostigmine would slow down muscle fatigability. However, 
no changes were found on the surface EMG during the treatment period in either of 
the two groups. The protocol used, with a sustained contraction at 40% of MVC (as 
obtained at baseline), did not induce high levels of fatigue, as was shown by the small 
decline in median frequency at baseline. This left little opportunity for improvement, 
and a relatively higher level of effort might have been more appropriate. 
 
Do subjects with normal sized motor units benefit more from pyridostigmine? 
It was hypothesised in advance that subjects with enlarged motor units would benefit 
most from pyridostigmine.9,15 Contrary to this expectation, subjects with normal sized 
motor units improved in walking performance, while those with enlarged motor units 
did not. Although this unexpected sub-group effect must be interpreted with caution, it 
should be realised that all quadriceps muscles were symptomatic, and all showed 
abnormal neuromuscular transmission. An explanation might be that the normal sized 
motor units were, in fact, enlarged motor units that had become reduced in size over 
time owing to the distal degeneration of axonal branches.12,38,39 
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CONCLUSIONS 
The result of this trial was negative, as pyridostigmine did not reduce fatigue in a 
selected group of subjects with postpoliomyelitis syndrome who were most likely to 
benefit from this treatment. On the other hand, the significant effect of pyridostigmine 
on walking distancetogether with some effects on walking duration, quadriceps 
strength, and maximal voluntary activationsuggest that pyridostigmine may improve 
muscle function. The effect of pyridostigmine might be related to the size of the motor 
units with neuromuscular transmission defects. In subjects with normal sized motor 
units, the effect size might be of relevance. However, a confirmatory study is needed 
as this finding resulted from a sub-group analysis that was not prespecified. 
Because no effect was found on perceived fatigue, future studies should 
concentrate on the effects of individually adjusted doses of pyridostigmine on 
physical performance in subjects with postpoliomyelitis syndrome. 
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ABSTRACT 
Objective: To compare walking test results with walking in daily life, and to investigate 
the relationships between walking tests, walking activity in daily life, and perceived 
mobility problems in patients with postpoliomyelitis syndrome. 
Subjects: Twenty-four ambulant patients with postpoliomyelitis syndrome. 
Methods: Walking tests were performed at self-preferred and maximal speed. 
Walking activity was measured with an ambulatory activity monitor. Heart rate, step 
cadence and walking speed in the test and in daily life were compared. Walking 
speed in daily life was represented by the intensity of walking. Perceived mobility 
problems were assessed with the Nottingham Health Profile. 
Results: Heart rate during walking was lower in the test at self-preferred speed than 
in daily life (mean difference: 11.3±10.4; P=0.001). Self-preferred walking speed in 
the test and in daily life correlated significantly (r=0.55; P=0.04). In a sub-group with a 
test performance below the median value, test performance correlated significantly 
with walking activity. No significant correlation was found between perceived mobility 
problems and walking activity. 
Conclusion: Walking in daily life may be more demanding than walking under 
standardized conditions. Patients with postpoliomyelitis syndrome with the lowest test 
performance walked less in daily life. Patients do not necessarily match their activity 
pattern to their perceived mobility problems. 
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aralytic poliomyelitis most often affects the muscles of the lower extremities. As 
a consequence, many individuals with late onset polio sequelae report a decline 
in walking ability.1,2 Limitation in walking activity is one of the most prominent 
problems of patients with postpoliomyelitis syndrome (PPS).3-5  
Walking capacity has been reported as an indicator of performance and activities 
of daily living (ADL) activity in patients with PPS.4,6-9 Frequently used methods to 
measure walking performance are time-scored tests at maximal or selfpreferred 
walking speed, usually carried out in a clinical setting.4,7,8 These standardized 
performance tests measure various aspects of walking, such as speed, distance and 
physical effort. 
Walking at comfortable speed in a clinical setting is assumed to represent walking 
in daily life.10,11 However, the level of effort and the characteristics of walking, such as 
speed and step cadence, during walking tests under standardized conditions may 
differ from those of walking in daily life, when conditions are not standardized. 
Therapeutic interventions for polio patients may aim at increasing their walking 
ability. It can be questioned whether walking ability in daily life, and changes in it, can 
be measured with walking tests. It seems likely that a relationship exists between 
walking test performance and the amount of walking in daily life.12 However, this 
relationship has never been investigated in patients with PPS. We hypothesized that 
walking test performance is an indicator of the amount of walking in daily life.  
In patients with PPS, perceived physical mobility problems were found to be 
related to performance in walking tests.4 However, it is unknown whether perceived 
mobility problems also imply that there is less actual walking activity. Therefore, it is 
important to investigate the relationship between perceived physical mobility 
problems and actual walking in daily life. 
 
Recently, we carried out a study to investigate the effects of pyridostigmine on fatigue 
in PPS patients.13 In that study, walking tests were performed at self-preferred and 
maximal speed, and the amount of walking in daily life was measured with an activity 
monitor.14 The activity monitor allows longterm (48 hours) continuous measurement 
of daily activities and physical effort with minimal influence on behaviour. Perceived 
P
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physical mobility problems were also measured in this study with a validated 
questionnaire. 
The purpose of the present study was threefold: (1) to investigate whether walking 
at self-preferred speed in a clinical setting reflects the levels of effort and 
characteristics of normal walking in the actual circumstances of daily life; (2) to 
investigate whether the performance in walking tests is related to the amount of 
walking in daily life; and (3) to investigate the relationship between perceived physical 
mobility problems and the amount of walking in daily life. 
 
METHODS 
The data were derived from the measurements of 24 patients with PPS (4 men and 
20 women) who were consecutively included in the pyridostigmine trial, who 
underwent ambulatory monitoring of their daily life activities.13 The mean age ± SD of 
these patients was 54.5±8.9 years. PPS symptoms had existed for an average of 
10.9±7.7 years, and all patients had new muscle weakness in at least 1 leg. All 
patients were able to walk for at least 2 minutes at self-preferred speed. Walking aids 
and orthopaedic devices were used in the walking tests in the same way in which 
they were used when walking outdoors. Nine patients used some type of walking aid 
(canes, crutches, orthosis). 
 
Outcome measures 
Walking tests 
Two tests were performed on a closed, marked 65-metre indoor, oval-shaped track. 
The patients first walked for 2 minutes at self-preferred speed and the distance was 
measured. They then walked 75 metres at maximal speed (without running) and the 
time was recorded. Each test was started after the patient had rested for 5 minutes, 
sitting on a chair. For each test, the mean walking speed was calculated from the 
distance and the time. When walking at selfpreferred speed, the patient’s heart rate 
was measured every 5 seconds with a Polar Sporttester.a Mean steady state heart 
rate was calculated from the recording period between 70 and 90 seconds after the 
patient had started walking. 
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When walking at self-preferred speed, a unilateral surface electromyography 
(EMG) of the patient’s quadriceps muscles was recorded with a portable ME300 
Muscle Tester.b Disposable surface electrodes (Medi-Trace Pellet, self-adhesive 
Ag/AgCl ECG electrodes; surface: 1cm2, centre-to-centre distance: 31mm) were 
placed over the vastus lateralis. Over the same period that was used to calculate the 
mean heart rate, the step cadence was determined from the peak amplitudes in the 
EMG signal.15 
 
Walking in daily life 
The activity monitor,c described in detail by Bussmann et al.,14 is based on long-term 
accelerometry. Signals from piezo-resistive accelerometers attached to the thighs 
and trunk were continuously measured and stored (32 Hz) on a portable data-
recorder. Data from ECG were recorded simultaneously. The patients’ data were 
recorded for a period of 48 hours in their regular daily life environment. After 
downloading the stored data onto a computer, several body postures and motions 
(walking included) were automatically detected from the accelerometer signals. The 
duration of walking was calculated as the percentage of time that a patient 
demonstrated walking activity (defined as walking for at least 5 seconds) in the 48-
hour recording period. In addition, ‘longer walking’ was determined as the duration of 
walking continuously for at least 30 seconds, and was expressed as a percentage of 
the 48 hours. 
Four walking periods of at least 120 seconds were selected to determine steady 
state heart rate, step cadence and motility (which is an indicator of walking speed). 
Patients had not performed strenuous activities in the 60 seconds before the start of 
these walking periods. The time-span between 2 periods was a minimum of 60 
minutes. Values were calculated from the recording interval between 70 and 90 
seconds after the onset of walking, and were averaged over the 4 walking periods. 
Heart rate was extracted from electrocardiographic data,16 and cadence was 
extracted from the pattern of the accelerometry data recorded from the thighs. Motility 
expresses the intensity of the accelerometry data. Its value depends on the variability 
of the accelerometer signal around the mean, i.e. the amplitudes of the peaks and the 
frequency of occurrence of these peaks.14 It has been shown that a strong 
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relationship exists between motility and walking speed, and that this relationship is 
independent of the efficiency of walking.16,17 
 
Perceived physical mobility problems 
Perceived mobility problems were assessed with the “physical mobility” category of a 
validated Dutch version of the Nottingham Health Profile (NHP).18 The score on the 
NHP physical mobility category was calculated as the percentage of the 8 items 
answered with “yes” (a perceived problem).  
 
The walking tests were performed and the NHP was administered during the second 
pre-medication study visit to the hospital.13 Within 7 days after the hospital visit, 
walking in daily life was measured with the activity monitor. 
 
Statistics 
Walking test results and walking in daily life were compared with respect to heart 
rate, cadence and walking speed, by means of t tests or Pearson’s correlation 
coefficient. The within-subject variability of heart rate, cadence and motility during 
walking in daily life over the 4 periods was determined with the coefficient of 
variation,19 calculated as: 
n
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, with )( ipσ as the standard deviation and ip as the mean of the 
4 periods of subject i, and n as the total number of subjects. 
The relationships between walking speed in the walking tests and the duration of 
walking and the duration of longer walking in daily life were analysed by calculating 
Pearson’s correlation coefficients. Relationships were studied for all patients, and for 
sub-groups, based on the median value of the walking test results, i.e. patients with a 
walking performance below the group median value and patients with a walking 
performance above the group median value. 
Relationships between perceived physical mobility problems and walking in daily 
life and walking test results were analysed by calculating Spearman’s correlation 
coefficients. The significance level was set at P<0.05. Statistical analysis was 
performed with the SPSS 10.0.5 software packaged. 
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RESULTS 
For the test at self-preferred speed, the mean walking speed was 1.02±0.17m/s, 
which was significantly lower (P<0.01) than the walking speed of 1.32±0.24m/s in the 
maximal test (mean difference: 0.31±0.16; 95%CI: 0.24–0.37). Walking at self-
preferred and maximal speed correlated significantly (r=0.75, P<0.01). For walking in 
daily life, the correlation between the duration of walking (6.6%) and the duration of 
longer walking (2.9%) was r=0.89 (P<0.01). 
Only 14 patients had walked at least 4 periods with a minimal duration of 120 
seconds. The coefficient of variation ± SD over these 4 periods was 5.1±2.0% for 
heart rate, 3.0±1.9% for cadence and 7.8±2.5% for motility. 
 
Characteristics of walking in the test at self-preferred speed compared with 
walking in daily life 
The mean heart rate in the walking test at self-preferred speed was significantly lower 
than when walking in daily life (P<0.01) (table 1). There was no difference between 
the cadence in the walking test and the cadence when walking in daily life. The 
correlation between cadence in the test and in daily life was r=0.46 (n.s.). The 
correlation between walking speed in the test and motility of walking in daily life was 
r=0.55 (P=0.04). 
 
Relationship between walking test performance and the duration of walking in 
daily life 
Both self-preferred and maximal speed in the walking tests correlated significantly 
with the duration of walking and longer walking in daily life (table 2). The strongest 
correlation was found between self-preferred speed and walking duration (r=0.52, 
P<0.01).  
For the sub-group with walking test results below the median value of the total 
group, significant correlations were found between walking test performance and 
walking activity in daily life. No significant correlations between walking test 
performance and walking activity in daily life were found for the sub-group with the 
better test performance results. 
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Table 1 Results of the walking test at self-preferred speed and walking in daily life  
 
 Walking test at 
self-preferred speed 
Walking in 
daily life 
Mean difference 95% CI; 
P value 
N=24     
Speed (m/s) 1.02±0.17    
Duration of walking  
(% time) 
 6.6±2.7   
Duration of walking 
>30s (% time) 
 2.9±1.7   
     
N=14     
Heart rate (beats/min) 98.6±9.2 110.0±14.0 11.3±10.4 5.4–17.3; 
P<0.01 
Cadence (steps/min) 107.6±10.0 109.1±6.6 1.5±9.1 -3.8–6.8; 
P=0.55 
Speed (m/s) 1.08±0.14    
Motility (g)  0.23±0.03   
The means ± SD are given for the outcome measures.  
One g is 9.8 ms-2. 
 
Relationship between perceived physical mobility problems and walking 
activity in daily life 
The median (25–75 percentile) score on the NHP physical mobility category was 25 
(16–50). The NHP physical mobility category correlated with the walking test 
performance for both self-preferred and maximal speed (table 3). The NHP physical 
mobility category did not correlate with the duration of walking or with longer walking 
in daily life. 
Chapter 7 
 
 113
Table 2 Relationship between walking test performance and the duration of walking in 
daily life 
 
 Walking in daily life 
Walking test performance Walking duration Walking duration >30s 
Self-preferred speed (n=24) 0.52** 0.50* 
sub-group low speed 0.65* 0.59* 
sub-group high speed -0.27* -0.24 
Maximal speed (n=24) 0.42* 0.46* 
sub-group low speed 0.73** 0.81** 
sub-group high speed 0.27 0.60* 
Pearson’s correlation coefficients are presented. Sub-groups were formed, based on the median value 
of the walking test results. Median values for self-preferred speed and maximal speed were 
respectively 1.05m/s and 1.29m/s.  
*P level below 0.05; **P level below 0.01. 
 
DISCUSSION 
The aim of the present study was to investigate the relationships between clinical 
walking tests, walking in daily life and perceived physical mobility problems in 
patients with PPS. Specifically patients with PPS were studied because they 
demonstrate an increase in neuromuscular symptoms and perceive a decline in 
walking ability.4,10 
It appeared that walking in daily life differed from walking under standardized 
conditions: the heart rate was significantly higher in daily life than in a test at self-
selected speed. This may be due to the less straining conditions during the walking 
test: the walking surface is flat and level, no additional tasks have to be performed, 
and there are no weather influences.  This is in contrast with a study in patients with 
chronic obstructive pulmonary disease, in which no difference was found in walking 
speed and heart rate between an indoor and outdoor 6-minute walking test.20
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However, the outdoor test in that study was performed under optimal conditions (a flat 
sidewalk in a quiet neighbourhood) and no additional tasks were carried out.  
The higher heart rate in daily life in the present study may also be due to carry-
over effects from previous activities. Although the walking periods from which the 
heart rate was determined with the activity monitor were all preceded by a period of 
relative rest, the walking tests were always preceded by a standardized period of 
absolute rest (5 minutes of sitting on a chair). 
 
Table 3 Relationship between perceived physical mobility problems, and duration of 
walking in daily life and walking test performance (n=24) 
 
 NHP physical mobility category 
Walking in daily life   
Walking duration -0.29 
Walking duration >30s -0.15 
Walking test performance  
Self-preferred speed -0.70** 
Maximal speed -0.69** 
Spearman's correlation coefficients are presented.  
* P<0.05; ** P<0.01. 
 
In contrast with heart rate, no systematic difference was found between cadence in 
the walking test at self-preferred speed and cadence when walking in daily life. 
However, the large standard deviation of the mean difference and the lack of 
correlation between the cadence in the walking test and in daily life indicate large 
within-subject variability between the 2 conditions. The small coefficient of variation 
(3%) for cadence in daily life suggests that this is not due to large within-subject 
variability of walking in daily life. It seems that the individual cadence when walking in 
the test differs from cadence when walking in daily life, but in different directions 
among patients. The cause of this remains speculative. 
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Both self-preferred walking speed and maximal walking speed were comparable to 
what has been found in an earlier study focusing on patients with PPS.21 The walking 
speed of patients with PPS is noticeably lower than that of healthy subjects.22 The 
percentage of walking activity in daily life of patients with PPS (6.6%) has also been 
found to be less than that of healthy subjects (9.1%), but higher than that of patients 
with chronic congestive heart failure (3.4%).23  
 
In the present study, significant relationships were found between walking test 
performance and the amount of walking in daily life. However, walking performance 
at self-preferred speed explained only 27% (r2=0.522; table 2) of the variance in 
duration of walking in daily life. This illustrates that actual walking in daily life is not 
only determined by walking ability. It is likely that daily life behaviour is largely 
determined by social behaviour, personal lifestyle, working conditions and living 
circumstances, such as the localization of shops, etc. Interestingly, much stronger 
relationships between walking test performance and walking in daily life were found 
for those patients with PPS with lower walking ability in the tests. Apparently, actual 
walking behaviour in these patients is mainly determined by their reduced walking 
ability. This is best illustrated by the variance in longer walking duration (>30 
seconds) that is explained for 66% (r2=0.812; table 2) by the performance in the 
maximal walking test. Maximal walking speed is apparently a better indicator of 
capacity than self-preferred walking speed for prolonged walking. 
One limitation of measuring behaviour is the day-to-day variability in daily life 
activities.23 Single-day measurements are probably not representative for a “general” 
level of daily activities. An attempt was made to take this into account by measuring 
for a period of 48 hours. However, it is still possible that variability between days may 
have affected some of the relationships found in this study.  
 
Both self-preferred and maximal speed in the walking tests were significantly related 
to perceived physical mobility problems. This is in agreement with the results of a 
study carried out by Nollet et al. in a different group of polio patients.4 Surprisingly, no 
significant relationships were found between perceived physical mobility problems 
and walking duration in daily life. This is in line with the results of a study carried out 
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by Willen et al., who found no significant relationship between the score on the 
Physical Activity Scale for the Elderly and the score on the NHP physical mobility 
category in patients with PPS.10 The lack of correlation between perceived physical 
mobility problems and walking in daily life might reflect the fact that certain tasks 
simply have to be performed in daily life, despite perceived limitations in physical 
performance. It is well known that patients with PPS tend to ignore or even deny their 
disabilities.24 
 
CONCLUSIONS 
In conclusion, the cardiac response of patients with PPS during walking in daily life 
was significantly higher than during walking in test circumstances. It may be that 
walking tests at self-preferred speed tend to under-estimate the physical effort of 
walking in daily life. Test performance was related to walking in daily life, and this 
relationship was most pronounced for those with the lowest test performance. 
Apparently, the limited capacity of these patients largely determined their physical 
behaviour. Although perceived physical mobility problems were related to walking 
test performance, they were not related to walking behaviour in daily life. This 
indicates that patients with PPS do not necessarily adapt their behaviour to their 
perceived capacities. Ambulatory monitoring of daily activities may be helpful in 
future studies that focus on changing actual behaviour in daily life. 
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he previous chapters of this thesis described the results of the randomised 
clinical trial (RCT) that was carried out to investigate the effects of 
pyridostigmine on fatigue, physical performance and muscle function in patients with 
postpoliomyelitis syndrome (PPS), and focused on the validity and reproducibility of 
the main outcome measures used in our trial. In the present chapter the methodology 
and the outcome of the trial are evaluated, the clinical implications are discussed, and 
some recommendations are made for future research.  
 
Methodological considerations 
The RCT described in this thesis was conducted to test the hypothesis that 
pyridostigmine reduces fatigue in patients with PPS. During the design of the trial we 
were informed by Trojan and colleagues about the results of their multicenter trial on 
pyridostigmine which they were about to publish.1 This gave us the opportunity to 
reflect on the methodology of our study and to include some of their suggestions 
concerning the design and the choice of outcome measures. It resulted in the 
incorporation of more specific outcome measures for fatigue and functional 
performance, the prescription of a higher dosage of pyridostigmine, and the selection 
of patients with PPS who were more likely to respond to pyridostigmine, namely 
those PPS patients with severe fatigue and with neuromuscular transmission defects, 
as demonstrated by stimulation single fibre electromyography (S-SFEMG). However, 
in our study we found no beneficial effect of pyridostigmine in these selected PPS 
patients. Only a limited and clinically non-relevant improvement in walking 
performance was found. There may be several reasons for these negative results.  
First, they could be due to methodological limitations. The primary outcome 
measure, the Nottingham Health Profile energy category, showed a severe ceiling 
effect, and all the questionnaires showed only moderate reproducibility.2 However, 
these limitations do not explain the negative results, since no effect was found on the 
other fatigue scores (such as the Fatigue Severity Scale), and because the mean 
changes on the fatigue outcomes were small.3 A recent study reported no difference 
in decline of frequency of the EMG signal during sustained contractions between the 
symptomatic muscles of patients with PPS and the muscles of healthy controls.4 This 
T 
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implies that determining muscle fatigue by the rate of decline in median frequency 
may not be appropriate in patients with PPS. 
Secondly, the significant but clinically non-relevant improvement in walking 
performance may be due to an insufficient dosage of pyridostigmine for some 
patients. Unfortunately, this could not be determined with certainty because the S-
SFEMG measurements that were used to assess the effectiveness of pyridostigmine 
were rather variable, probably due to a wide variation in neuromuscular transmission 
defects between end-plates.  
Another explanation might be that our trial was based on the wrong assumption. 
We assumed that the increased fatigue in patients with PPS was due to increased 
muscle fatigability, caused by neuromuscular transmission defects. We hypothesized 
that pyridostigmine would improve neuromuscular transmission, and thereby muscle 
function, and would eventually reduce fatigue. However, increased neuromuscular 
transmission defects may only be one of the possible causes of fatigue in PPS. 
Defects in the neuromuscular transmission are present but not always observed in 
post-polio subjects with a reduction in muscle strength and increased fatigability.4 It 
has been found that there can be several other causes of fatigue in patients with 
PPS, such as impaired calcium kinetics (leading to disturbances in excitation 
contraction coupling of the actine and myosine filaments),5 decreased capillary 
density and oxidative and glycolytic enzyme potentials,6 impaired voluntary muscle 
activation (that can be due to impaired reflex mechanism),7,8 degeneration of neurons 
of the reticular formation and basal ganglia,9 chronic pain, respiratory dysfunction, 
and sleep disorders.10 Therefore, it is conceivable that transmission failures, although 
present, may not have been the primary cause of fatigue in an unknown number of 
patients in our study.  
Although the fatigue that was measured with the questionnaires resembled one 
construct, this does not imply that fatigue can only be due to increased transmission 
failures. Therefore, it would be necessary to study the determinants of fatigue in PPS 
in general and, for the purpose of our study in particular, in patients with increased 
neuromuscular transmission defects. This type of preliminary investigation was 
ignored in our study, but might have resulted in different inclusion criteria that would 
have ensured the inclusion of only those patients whose overall fatigue was, indeed, 
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primarily determined by muscle fatigue, and who were therefore more likely to 
respond to pyridostigmine. 
 
Benefit of pyridostigmine in sub-groups? 
The question that remains is whether there is a sub-group of patients with PPS for 
whom pyridostigmine would decrease fatigue. The different sub-group analyses 
described in Chapter 6 did not reveal any evidence for a beneficial effect in patients 
with large motor units, with reduced quadriceps strength, or with reduced comfortable 
walking speed. However, in Chapter 7, we found a significant relationship between 
walking capacity measured in time-scored walking tests and the amount of walking 
activity in daily life in patients with a limited walking capacity. The highest correlation 
was found for the test at maximal walking speed: after dichotomizing, the patients 
with low maximal walking speed walked less in actual daily life, i.e. in their normal 
environment. In fact, 66% of the variance in their walking activity in daily life was 
explained by the variance in maximal walking speed (P<0.01). This may imply that 
the performance of these patients is, to a large extent, determined by their capacity to 
generate muscle strength, which depends not only on muscle mass, but also on 
physiological characteristics of the muscle-nerve complex, such as the quality of 
neuromuscular transmission.  
A reduced capacity of muscles to generate strength may have major 
consequences for daily life activities, especially in patients with severe paresis, 
because neuromuscular transmission failure may significantly add to their muscle 
fatigue. In addition, neuromuscular transmission failure in patients with low muscle 
strength capacity may increase during the execution of a certain task and force the 
patient to limit certain physical activities (i.e. walking) and, as a result, the amount of 
walking will decrease.  
 
If the performance of patients with low muscle strength is, indeed, partly due to 
impaired neuromuscular transmission, then these patients should benefit from 
pyridostigmine treatment. To test this hypothesis an additional sub-group analysis 
was performed. A distinction was made between patients with “high” and “low” 
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walking capacity, based on the group median value of maximal walking speed. Table 
1 shows the baseline characteristics of PSS patients with low walking capacity in the 
walking test at maximal speed. No differences in baseline characteristics were found 
between the pyridostigmine and placebo-treated patients. 
 
Table 1 Baseline characteristics, according to treatment group, for PPS patients with 
low walking capacity in the walking test at maximal speed 
 
Characteristics / outcome measures Pyridostigmine 
(n=16) 
Placebo 
(n=16) 
P Value 
Age (years) 53±9 52±9 0.66 
Gender (M/F ) 5/11 5/11 1.00 
Age at polio onset (years) 4.5±5.4 2.6±2.8 0.23 
Duration of PPS symptoms (years) 10.1±7.6 10.5±6.6 0.86 
Severity of paresis of the legs (range 0–32) 22±5 18±6 0.07 
Motor unit size (mV·ms) 2.3±1.2* 3.5±2.6† 0.13 
Short Fatigue Questionnaire 
(range 1–7) 
5.4±1.1 4.7±1.2 0.08 
Nottingham Health Profile, energy category 
(range 0–100) 
56±34 46±36 0.41 
Fatigue Severity Scale (range 1–7) 5.8±0.6 5.7±0.9 0.80 
Two-minute walking distance, comfortable 
speed (m) 
108±16 98±24 0.20 
Maximal walking performance, 75m (s) 68±13 77±24 0.20 
Walking duration (percentage of total time) 5.8±3.9‡ 6.3±2.8|| 0.83 
Quadriceps strength (Nm) 82±45 77±53 0.76 
Maximal voluntary activation (range 0–100) 68±18¶ 69±21* 0.82 
Muscle fatigability on surface EMG 
(MF0-5s-MF25-30s) 
1.1±2.1¶ 2.8±3.0¶ 0.12 
Neuromuscular transmission, jitter (µs) 40±15 45±16 0.36 
With the exception of gender, values are presented as mean ± SD. Differences between the two 
groups were tested with t tests (χ2 for gender). 
*n=13; †n=15; ‡n=5; ||n=6; ¶n=14 
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The results of this sub-group analysis are presented in table 2. They show that when 
the patients with low maximal walking speed (<50th percentile) were treated with 
pyridostigmine, they improved significantly more in perceived fatigue on the Fatigue 
Severity Scale (1 scale point, P=0.04 ), in walking capacity (both comfortable [10%, 
P<0.01] and maximal walking speed [5%, P=0.03], in maximal quadriceps strength 
(20%, P=0.03), and in maximal voluntary activation (13%, P=0.05) than when they 
were treated with placebo.  
The severity of paresis can be used as an indicator of muscle strength, and was 
calculated as the sum of the strength of 16 lower extremity muscle groups, based on 
scores from manual muscle testing.3,11 For the whole study population at baseline, it 
was found that maximal walking speed was strongly related to this sum score of 
muscle strength (r=0.63; P<0.01). Therefore, in the group of patients with low walking 
capacity, pyridostigmine may have a beneficial effect on fatigue and walking capacity 
by improving the limiting factor, which is muscle strength, as is demonstrated by the 
significant increase in quadriceps strength and voluntary activation in these patients. 
Table 2 also shows that patients with high maximal walking speed (>50th 
percentile) do not benefit from pyridostigmine treatment on any outcome measure. It 
is unlikely that the significant effects found on five outcome measures (although not 
on the primary outcome measure), in the sub-group of patients with low walking 
capacity, while no statistically significant effects were found in the patients with high 
walking capacity, is merely due to chance resulting from multiple testing or is to be 
explained by data-fishing. 
 
The percentages of improvements in quadriceps strength and voluntary activation are 
substantial, but may reflect only small changes in absolute strength.12 Still, even 
small changes may have clinical relevance; for some patients it could mean that they 
regain some of their functional capabilities. Although fatigue measured with the 
Fatigue Severity Scale improved significantly, fatigue according to the primary 
outcome measure (Nottingham Health Profile energy category), and muscle 
fatigability did not improve. This may be due to the methodological limitations of these 
outcome measures, as described in Chapter 3. 
  
T
ab
le
 2
 C
ha
ng
es
 i
n 
ou
tc
om
e 
m
ea
su
re
s 
fr
om
 t
he
 s
ec
on
d 
ba
se
lin
e 
m
ea
su
re
m
en
ts
 a
t 
14
 w
ee
ks
 o
f 
tr
ea
tm
en
t, 
ac
co
rd
in
g 
to
 
tr
ea
tm
en
t g
ro
up
 
  
S
ub
-g
ro
up
: m
ax
im
al
 w
al
ki
ng
 s
pe
ed
 a
t b
as
el
in
e 
<
 4
.7
 k
m
/h
 
S
ub
-g
ro
up
: m
ax
im
al
 w
al
ki
ng
 s
pe
ed
 a
t b
as
el
in
e 
>
 4
.7
 k
m
/h
 
 
P
yr
id
os
tig
m
in
e 
(n
=
16
) 
P
la
ce
bo
 
(n
=
16
) 
∆
 (
95
%
 C
I)
 
P
 v
al
ue
 
P
yr
id
os
tig
m
in
e 
(n
=
17
) 
P
la
ce
bo
 
(n
=
15
) 
∆
 (
95
%
 C
I)
 
P
 v
al
ue
 
N
ot
tin
gh
am
 H
ea
lth
 P
ro
fil
e 
en
er
gy
 c
at
. 
(r
an
ge
 0
–1
00
) 
-1
3.
3 
(3
7.
4)
 
-1
0.
4 
(3
1.
5)
 
-2
.9
 (
-2
8.
3 
to
 2
2.
4)
 
0.
82
 
-2
2.
9 
(3
5.
9)
 
-2
3.
8 
(3
5.
6)
 
0.
9 
(-
25
.9
 to
 2
7.
7)
 
0.
95
 
F
at
ig
ue
 S
ev
er
ity
 S
ca
le
 (
ra
ng
e 
1–
7)
 
-0
.9
 (
1.
0)
 
-0
.2
 (
0.
8)
 
-0
.7
 (
-1
.4
 to
 -
0.
1)
 
0.
04
 
-0
.3
 (
0.
6)
 
-0
.7
 (
0.
9)
 
0.
4 
-0
.2
 to
 1
.0
) 
0.
17
 
Q
ue
st
io
n 
1 
0.
7 
(0
.9
) 
0.
4 
(0
.8
) 
0.
3 
(-
0.
3 
to
 0
.9
) 
0.
34
 
0.
3 
(0
.9
) 
0.
7 
(1
.0
) 
-0
.5
 (
-1
.2
 to
 0
.2
) 
0.
18
 
S
ub
je
ct
iv
e 
be
ne
fit
 o
f 
tr
ea
tm
en
t 
Q
ue
st
io
n 
2 
0.
8 
(0
.8
) 
0.
6 
(1
.1
) 
0.
2 
(-
0.
5 
to
 0
.9
) 
0.
61
 
0.
2 
(0
.9
) 
0.
5 
(0
.8
) 
-0
.3
 (
-1
.0
 to
 0
.3
) 
0.
32
 
T
w
o-
m
in
ut
e 
w
al
ki
ng
 d
is
ta
nc
e 
(m
) 
13
.3
 (
8.
9)
 
3.
3 
(9
.0
) 
10
.0
 (
3.
4 
to
 1
6.
6)
 
0.
00
4 
7.
4 
(9
.1
) 
3.
6 
(8
.5
) 
3.
8 
(-
2.
9 
to
 1
0.
4)
 
0.
25
 
M
ax
im
al
 w
al
ki
ng
 p
er
fo
rm
an
ce
, 7
5 
m
 (
s)
 
-3
.6
 (
4.
1)
 
0.
4 
(5
.2
)*
 
-4
.0
 (
-7
.5
 to
 -
0.
4)
 
0.
03
 
0.
3 
(3
.8
) 
-0
.1
 (
2.
3)
 
0.
4 
(-
1.
9 
to
 2
.8
) 
0.
70
 
D
ur
at
io
n 
of
 w
al
ki
ng
 (
%
 o
f t
ot
al
 ti
m
e)
 
1.
5 
(1
.7
)†
 
1.
5 
(1
.6
)‡
 
0.
0 
(-
2.
3 
to
 2
.2
) 
0.
98
 
1.
6 
(1
.0
)‡
‡  
-0
.1
 (
1.
8)
§§
 
1.
6 
(-
0.
4 
to
 3
.6
) 
0.
10
 
Q
ua
dr
ic
ep
s 
st
re
ng
th
 (
N
m
) 
19
.2
 (
25
.2
) 
3.
5 
(1
2.
2)
 
15
.7
 (
1.
4 
to
 3
0.
1)
 
0.
03
 
6.
6 
(1
5.
7)
 
8.
8 
(1
5.
1)
 
-1
.3
 (
-1
4.
8 
to
 1
2.
1)
 
0.
84
 
M
ax
im
al
 v
ol
un
ta
ry
 a
ct
iv
at
io
n 
(r
an
ge
 0
–1
00
) 
11
.1
 (
13
.9
)§
 
-2
.0
 (
14
.7
)¶
 
13
.1
 (
0.
3 
to
 2
6.
0)
 
0.
05
 
5.
1 
(1
4.
3)
¶¶
 
6.
4 
(1
2.
3)
‡
‡  
-2
.2
 (
-1
3.
7 
to
 9
.4
) 
0.
70
 
M
us
cl
e 
fa
tig
ab
ili
ty
 (
M
F
0-
5s
-M
F
2
5-
30
s)
 
2.
1 
(3
.7
)¶
 
0.
4 
(3
.7
)*
*  
1.
6 
(-
1.
6 
to
 4
.8
) 
0.
30
 
-0
.1
 (
2.
8)
*  
0.
2 
(3
.0
)*
 
-0
.3
 (
-2
.5
 to
 2
.0
) 
0.
80
 
N
eu
ro
m
us
cu
la
r 
tr
an
sm
is
si
on
, 
jit
te
r 
(µ
s)
 
-9
.3
 (
9.
3)
 
-1
.7
 (
21
.8
)*
 
-7
.6
 (
-2
0.
2 
to
 5
.0
) 
0.
23
 
-2
.1
 (
20
.2
) 
-4
.0
 (
22
.0
)¶
¶  
2.
0 
(-
14
.1
 to
 1
8.
1)
 
0.
80
 
R
es
ul
ts
 a
re
 p
re
se
nt
ed
 f
or
 s
ub
-g
ro
up
s 
ba
se
d 
on
 t
he
 g
ro
up
 m
ed
ia
n 
va
lu
e 
of
 m
ax
im
al
 w
al
ki
ng
 s
pe
ed
. 
C
ha
ng
e 
is
 c
al
cu
la
te
d 
as
 t
he
 s
co
re
s 
at
 
in
te
rv
en
tio
n 
m
in
us
 t
he
 s
co
re
s 
at
 b
as
el
in
e 
an
d 
is
 p
re
se
nt
ed
 a
s 
m
ea
n 
(S
D
).
 T
he
 d
iff
er
en
ce
 i
n 
ch
an
ge
 b
et
w
ee
n 
gr
ou
ps
 (
∆
) 
is
 c
al
cu
la
te
d 
fr
om
 t
he
 
ch
an
ge
 in
 t
he
 p
yr
id
os
tig
m
in
e 
gr
ou
p 
m
in
us
 t
he
 c
ha
ng
e 
in
 t
he
 p
la
ce
bo
 g
ro
up
 a
nd
 is
 p
re
se
nt
ed
 a
s 
m
ea
n 
di
ffe
re
nc
e 
(9
5%
 c
on
fid
en
ce
 in
te
rv
al
) 
an
d 
th
e 
P
 v
al
ue
 o
f t
he
 t 
te
st
. *
n=
14
; †
n=
5;
 ‡
n=
6;
 §
n=
10
; ¶
n=
12
;**
n=
11
; †
† n
=
9;
 ‡
‡ n
=
7;
 §
§ n
=
3;
 ¶
¶ n
=
13
. 
C
I, 
co
nf
id
en
ce
 in
te
rv
al
; M
F
, m
ed
ia
n 
fr
eq
ue
nc
y.
 
Chapter 8 
 
 127
However, it could also be due to the fact that, as a result of pyridostigmine treatment, 
the patients increased their level of daily life activities, i.e. the amount of walking. This 
would imply that the fatigue itself is not necessarily reduced. However, this remains 
speculative, due to the lack of sufficient data on daily life activities. In a very small 
group of only 5 patients with poor maximal walking capacity, no increase was found 
in walking duration in daily life due to pyridostigmine treatment. It would be interesting 
to investigate this in a larger group of patients. 
The conclusion of this additional sub-group analysis is that patients with low 
walking capacity, i.e. with more severe paresis resulting in little walking activity in 
daily life, may benefit from pyridostigmine treatment. Their performance may be 
strongly determined by their limited capacity to generate muscle strength, which may 
improve while pyridostigmine improves the neuromuscular transmission.  
The walking activity in daily life of patients with greater walking capacity is 
probably not primarily determined by the capacity to generate muscle strength, but 
rather by personal and environmental factors. Therefore, an increase in muscle 
strength, due to improved neuromuscular transmission, will not necessarily change 
their performance in daily life. Moreover, the transmission disturbances during 
sustained contractions may not increase during activities for which the demands on 
the muscle system are relatively low. Thus, transmission defects in these patients 
may have very little influence on their fatigue and daily behaviour, and these patients 
are not expected to benefit from pyridostigmine treatment. 
Although the above-mentioned sub-group analysis concerning walking capacity 
was performed after, and in addition to the analyses described in Chapter 6, the 
results suggest that pyridostigmine can not be ruled out as a treatment option to 
improve muscle function and performance in some patients with PPS. The clinical 
relevance of pyridostigmine for PPS patients with poor walking capacity, due to low 
muscle strength, needs to be confirmed in further studies. 
 
Encouraging the evaluation of capacities 
The severity and the progression of PPS are frequently assessed with measures at 
the level of muscle function.13,14 However, Chapters 4 and 6 showed that outcome 
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measures such as quadriceps strength (measured with a fixed dynamometer), 
voluntary activation (measured with twitch-interpolation), and neuromuscular 
transmission defects (measured with S-SFEMG) have a wide variability. They 
therefore lack the precision to reliably determine the severity of impairments in 
muscle function, and they lack the sensitivity to identify changes over time, given the 
usually slow decline in muscle function in patients with PPS.15,16  
Symptoms and functioning are often assessed with validated questionnaires.17,18 
In our study, questionnaires were used to assess perceived health, fatigue and rating 
of exertion. Chapters 3 and 5 have shown that the reproducibility of these measures 
is also poor, and that their ability to detect changes, particularly at individual level, is 
limited. Apparently, it is difficult to achieve a reliable measurement of function and 
functioning in patients with PPS. Moreover, there is a wide gap between actual body 
functions on the one hand, and the perception of functioning of patients on the other 
hand. 
Apart from describing outcome at the level of body functions and structures, 
outcomes at the level of activity and participation should also be assessed. With 
regard to the activity and participation level, two important qualifiers are provided in 
the International Classification of Functioning, Disability and Health (ICF).19 The 
Performance qualifier describes what an individual does in his or her daily life 
environment, and the Capacity qualifier describes the ability of an individual to carry 
out activities in a standardized environment, for instance in a test setting.  
In our studies, performance with regard to walking in daily life was measured with 
ambulatory accelerometry, and the capacity to walk was measured with standardized 
walking tests. These measurements provided valuable additional information that 
eventually enabled us to differentiate between patients with PPS who did and who did 
not respond to pyridostigmine treatment. 
In the RCT, walking capacity was measured at self-preferred and at maximal 
walking speed. Apart from studying the reliability of both walking tests, combining the 
results from the different studies provided more insight into the validity of these tests, 
because they supply different information and may therefore serve different 
purposes. In Chapter 5 it was shown that the two walking tests had good test-retest 
reproducibility, and that they were sensitive enough to detect relatively small 
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changes. Since both tests showed equal reproducibility, we concluded that the choice 
of a test must be based on other arguments. An important argument suggesting that 
the two tests do provide different information became apparent in the study of the 
relationships between walking capacity, walking in daily life and perceived mobility 
problems, as described in Chapter 7. It was found that both walking tests correlated 
significantly with walking performance in daily life. This was not surprising, since 
walking at self-preferred speed correlated strongly with walking at maximal speed, 
explaining 68% of the variance between the results (figure 1). 
 
Figure 1 Scatter plot of self-preferred versus maximal walking speed at baseline. The 
squared correlation coefficient (r2) indicates the explained variance in results. 
 
However, it appeared that maximal walking test results in patients with the lowest 
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daily life (r=0.81; P<0.01)(see Chapter 7). Apparently, the load on the available 
muscle capacity in walking at self-preferred speed varies between patients, which 
implies that different patients use different walking strategies. For instance, some 
patients may walk at a relatively high speed, maybe at the cost of the walking 
distance, while others walk at a slow speed, using less of the available capacity, and 
may therefore be capable of walking longer distances. Such inter-individual 
differences may primarily depend on personal and environmental factors.  
An important finding was already addressed earlier in this chapter, namely that 
maximal walking capacity discriminated between sub-groups with respect to 
response to pyridostigmine. In view of this trial, which aimed to improve functioning 
by increasing muscle function, we therefore conclude that maximal walking tests are 
a better indicator of walking capacity in patients with PPS, and are therefore more 
preferable than tests at self-preferred speed. However, this does not imply that 
walking tests at self-preferred speed are of no value; this depends on the purpose of 
the testing. For example, capacity tests at sub-maximal effort levels could be more 
appropriate if the aim is to achieve changes at this level, for instance to lower the 
energy demands of walking at self-preferred speed, to increase self-preferred walking 
speed, or to increase walking distance.  
 
Our findings emphasize the potential value of capacity outcome measures that 
evaluate performance in a standardized environment. They may hold an important 
position between impairments of body functions underlying the disabilities, on the one 
hand, and daily life functioning on the other hand.20 First, by relating standardized 
capacity evaluation to muscle function one can study the impairments in body 
functions that are responsible for restrictions in functional abilities. This may lead to 
more specific, and thus more effective intervention strategies. Secondly, by relating 
standardized capacity evaluation to measurements of performance in daily life and 
perceived functional problems, one can study the consequences of loss of functional 
abilities for daily life behaviour and participation.  
Therefore, by understanding and developing specific standardized measurements 
to evaluate capacities, rehabilitation can aim to target interventions at the level of 
body function and structures or at the level of functional skills, in order to improve the 
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performance of daily life activities within the environmental and personal context. 
Measurement of standardized performance should therefore be a key aspect of 
functional evaluation, and an important outcome in clinical trials. 
 
Recommendations for future research 
The fact that patients with PPS often complain about general fatigue,9,10 and/or 
fatigue related to physical activity, such as increased muscle fatigability21 and 
delayed recovery,22 suggests that different forms of fatigue may be present in PPS. 
To gain more insight into this complex phenomenon of fatigue in PPS, it is therefore 
necessary to distinguish between the different forms of fatigue. The main question is 
whether there is one predominant form of fatigue that can be established as the most 
disabling. Studying the characteristics of different forms of fatigue also provides 
information about their contribution to the overall fatigue perception, and makes it 
possible to make comparisons with other illnesses in which fatigue is a major 
symptom (such as multiple sclerosis) with respect to the relationship between fatigue 
and the ability to engage in activities, and with respect to strategies to compensate 
the fatigue.23 
In addition to distinguishing between the different forms of fatigue in patients with 
PPS it is also necessary to identify the determinants of (each separate form of) 
fatigue. It has already been mentioned that there are many possible causes for 
fatigue in PPS, ranging from global to specific origins.5-10,24 Knowledge about the 
determinants of fatigue will not only contribute to our understanding of the origin of 
fatigue in PPS, but will also give direction to interventions aiming to reduce fatigue in 
(selected groups of) PPS patients.  
Finally, it is also important to study the impact of fatigue on the daily life of patients 
with PPS. The main objective is to determine the consequences of fatigue on daily 
life functioning and to investigate whether this impact differs for the various forms of 
fatigue. Information should be gathered to determine the relationship between fatigue 
and performance, both in a standardized and in a daily life environment.  
To investigate the characteristics, determinants, and impact of different forms of 
fatigue in patients with PPS a descriptive study in a large unselected population of 
General discussion 
 
 132 
patients with PPS is required. Such a study should make a detailed inventory of the 
characteristics of fatigue and investigate a broad range of potential determinants, 
including outcomes at the level of muscle function and at the level of performance, 
both in a standardized and in a daily environment. In particular, attention should be 
paid to the objective assessment of muscle fatigue. It has already been mentioned 
that surface and single fibre EMG lack sufficient validity and reliability for this 
purpose. Efforts should be made to improve such measures. A technique that has 
recently become available to assess muscle fatigability is 31P magnetic resonance 
spectroscopy, which quantifies the chemical status of a muscle by determining 
concentrations of phosphate metabolites.5,25 Unfortunately, such measurements are 
complicated and costly, and are not yet applicable for all muscles. 
 
Earlier in this discussion it was stated that PPS patients with a limited walking 
capacity improved on pyridostigmine treatment with respect to fatigue, muscle 
strength and walking capacity. It was suggested that in these patients, in particular, 
neuromuscular transmission defects might be an important cause of fatigue. A first 
step in verifying this hypothesis would be to study the change in transmission quality 
and muscle fatigability during standardized activities, in relation to muscle strength 
capacity. To study the relationship between fatigue and neuromuscular transmission 
quality it is necessary to develop a reliable method to measure transmission defects 
in large lower extremity muscles.  
The results of the sub-group analysis encourage further investigation of 
pyridostigmine treatment in patients with PPS. To determine whether pyridostigmine 
has a clinically relevant effect on fatigue and functioning in patients with PPS a new 
trial should be conducted in a larger group of patients with low walking capacity. It 
could be argued that instead of concentrating on the complex and multi-factor 
outcome of fatigue, walking capacity should be taken as the primary outcome 
measure. The advantage of this approach is that walking capacity can be measured 
with high precision, whereas fatigue may remain unaltered if patients increase their 
activity levels. Therefore, additional information should be collected on the effect of 
treatment on activities in the daily life of patients with PPS. To increase the 
effectiveness of pyridostigmine, the dose should be individually adjusted and 
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preferably be prescribed in a slow release form to stabilize the plasma concentration 
throughout the day. Only if such a trial is carried out will we obtain a definite answer 
to the question of whether or not pyridostigmine is effective in the treatment of 
selected patients with PPS. 
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n the past it was generally assumed that the residual neurological deficits from 
polio would remain stable throughout life. However, in the late seventies of the 20th 
century large numbers of polio survivors started to complain about new 
neuromuscular symptoms. Inventory studies demonstrated that the main symptoms 
were progressive and persistent (new) muscle weakness, abnormal muscle 
fatigability, muscle atrophy and muscle and joint pain. These symptoms have been 
termed the postpoliomyelitis syndrome (PPS). The course of PPS is slowly 
progressive and negatively affects functioning in daily life. The main problems are 
fatigue and decreasing physical mobility, which negatively affect the level of 
independency and decrease life satisfaction. 
 
Poliomyelitis is an infectious viral disease that primarily affects motor neurons and 
causes an acute, flaccid paresis of a varying number of muscle groups. After the 
acute polio, motor neurons that have survived the acute stage recover and regain 
their function. Denervated muscle fibres from permanently lost motor neurons are 
reinnervated through collateral sprouting from surviving axons, and as a result motor 
units increase in size. Muscle fibre hypertrophy occurs to compensate for the loss in 
strength. At the end of recovery, a varying degree of residual paresis remains, 
providing stable muscle strength and functioning for several decades. 
It is supposed that the enlarged motor units following polio do not remain stable 
throughout life, but degenerate prematurely due to persistent high metabolic stress 
on the motor neurons. The degeneration of motor units results in a slowly progressive 
loss of axonal sprouts and consequently, a gradual decline in strength. In addition, it 
has been suggested that, prior to degeneration of terminal axons, abnormalities in 
neuromuscular transmission occur, which may cause or increase symptoms such as 
fatigue and reduced endurance. The presence of transmission defects at the 
neuromuscular junctions has been confirmed in stimulation single fibre EMG studies. 
In 1993 Trojan and Cashman suggested that the transmission defects may partly 
be due to a defect in the release of the neurotransmitter acetylcholine. To improve the 
effectiveness of acetylcholine, Trojan and co-workers studied the effect of the 
anticholinesterase inhibitor pyridostigmine. In a randomised controlled multicenter 
trial, no effect was found of 180 mg pyridostigmine per day for a period of 6 months 
I 
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on physical functioning, muscle strength, and fatigue. However, the negative results 
of this trial may be due to methodological limitations of the study design with respect 
to patient selection, outcome measures and the dosage of pyridostigmine used.  
The letter in Chapter 2 is a reaction to the results published by Trojan and co-
workers and is a critical contemplation of the methodology and design of their trial. 
The criticism primarily focuses on the lack of responsiveness of the outcome 
measures and the heterogeneity of the study population. It is concluded that the 
results of their trial do not exclude pyridostigmine as a possible beneficial treatment 
for patients with PPS. This conclusion encouraged us to proceed with a randomised 
trial we had initiated around that time, in which the effect of pyridostigmine on the 
symptoms of PPS was investigated. In comparison with the trial of Trojan and co-
workers, important methodological differences in our study design are that symptom 
specific outcome measures are applied, a homogeneous patient group is composed, 
and that the dose of pyridostigmine is raised to 240 mg per day. 
 
Chapters 3, 4 and 5 report on the validity and reproducibility of the most important 
outcome measures used in the trial: fatigue questionnaires, maximal muscle strength 
measurements and walking capacity measurements. In 65 patients with PPS two 
baseline measurements of fatigue, muscle strength and walking capacity were 
performed with a 3-week period in between. 
 
Different questionnaires have been used to measure the severity of fatigue in patients 
with PPS. Comparing results obtained with different questionnaires is problematic, 
because it is not known whether the differences in scores reflect differences in the 
severity of fatigue between the study populations or differences in the response 
characteristics of the questionnaires. In addition, the sensitivity to detect change of 
questionnaires that measure fatigue in patients with PPS has not yet been described.  
In Chapter 3, the comparability and reproducibility are investigated of four 
questionnaires that are frequently used to determine the severity of the fatigue in 
patients with PPS: The Fatigue Severity Scale (FSS; scale range 1–7), the 
Nottingham Health Profile (NHP) energy category (scale range 0–100), the Polio 
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Problem List (PPL) fatigue item (scale range 0–7), and the Dutch Short Fatigue 
Questionnaire (SFQ; scale range 1–7).  
The mean normalised total scores at the second visit were highest (meaning 
severe fatigue) for the PPL fatigue item (81±17) and lowest for the NHP energy 
category (47±35). The correlations of scores between questionnaires were all 
significant and ranged from .43 between the NHP energy category and the PPL 
fatigue item to .68 between the PPL fatigue item and the SFQ. The differences in 
scores between the questionnaires were significant, except for the difference 
between the FSS and the PPL fatigue item. Mokken scale analysis to examine 
construct validity indicated that all questionnaires measured the same unidimensional 
construct. The reproducibility of the FSS, the PPL fatigue item, and the SFQ was 
moderate. The smallest detectable change was 1.5 scale points for the FSS, and 2 
scale points for the PPL fatigue item and the SFQ.  
It is concluded that, for patients with PPS, the questionnaires measure the same 
fatigue construct, but the score for fatigue, reflecting its severity, may differ 
considerably as a result of differences in the range for which questionnaires measure 
fatigue. The moderate reproducibility of the questionnaires indicates a lack of 
precision, especially when applied at the individual patient level. The choice of the 
appropriate questionnaire to measure fatigue in PPS may depend on the expected 
range in the severity of fatigue and the desired responsiveness of the questionnaire. 
 
Long-term studies have estimated the decline in muscle strength in patients with PPS 
at 1-2% per year. It is questionable whether an individual decline in strength can be 
identified within several years. There are no data on the ability to detect a change in 
strength with a fixed dynamometer in individual patients with PPS. In subjects with a 
history of polio, impaired maximal voluntary muscle activation has been found. 
Variability in activation will lead to variability in strength, and may therefore contribute 
to the variability in muscle performance. Therefore, the objectives in Chapter 4 are to 
determine what changes in maximal strength can be detected in a symptomatic 
quadriceps muscle in patients with PPS and to investigate the association between 
the variability in maximal strength and maximal voluntary activation.  
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Isometric voluntary peak torque is measured at optimal knee angle, and maximal 
voluntary activation is determined by twitch interpolation. The difference in strength 
between the 2 measurements for the whole group was small and not significant. The 
test-retest reliability was excellent for maximal strength (ICC=.96) and moderate for 
maximal activation (ICC=.73). The smallest decline in strength that can be detected 
at group level is 4.5%. However, at the individual level, only a decline in strength 
larger than 25% can be detected. The mean maximal activation at both visits was 
67% of full activation. The variability in maximal activation explained 18% of the 
variability in maximal strength. 
It is concluded that variability in maximal quadriceps strength, measured with a 
fixed dynamometer, is large and is only partly related to the variability in maximal 
activation. This implies that even in optimal standardized conditions, it is not possible 
to detect small changes in the strength of symptomatic quadriceps muscles with a 
fixed dynamometer in individual patients with PPS. However, the reproducibility is 
sufficient to evaluate changes in groups of subjects in both follow-up (of more than 4 
years) and intervention studies. The limited influence of variability in maximal 
voluntary activation on the variability in strength may be caused by the curvilinear 
relationship between voluntary activation and force, and by co-activation of the 
hamstrings. 
 
Walking capacity is usually measured with timed walking tests. Whether such tests 
are appropriate to determine a decline in walking capacity depends largely on their 
reproducibility. Physical effort during walking can be measured objectively by 
recording the heart rate, but also by rating the perceived exertion. Recently, patients 
with PPS have been recommended to use a perceived exertion Borg scale in daily life 
to avoid excessive fatigue. Whether such scale is appropriate for this purpose 
depends on its stability across measurements and on its relation with the actual effort 
and performance. Chapter 5 report on the reproducibility of, and the associations 
between walking capacity, heart rate, and perceived exertion at self-preferred and 
maximal walking speed in patients with PPS. 
It was found that test-retest reliability of walking capacity was excellent for both 
tests (ICC range, .94–.97). The smallest detectable change for an individual was 15% 
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for both tests. Test-retest reliability for heart rate was good (ICC=.86) and moderate 
for perceived exertion (Spearman ρ range .67–.70). The smallest detectable change 
for perceived exertion was between 4 and 6 scale points. The variability in walking 
capacity was significantly correlated with the variability in heart rate but not with the 
variability in perceived exertion. 
The good reproducibility of both walking tests makes them appropriate to monitor 
(individual) changes in walking capacity in patients with PPS. Because no difference 
existed in reproducibility between the tests at different speeds, the choice of test must 
be based on other criteria. Because of the moderate reproducibility of perceived 
exertion, it does not seem to be suitable to monitor physical exertion in patients with 
PPS in order to avoid overloading. 
 
Chapter 6 describes the results of the randomised, double-blind, placebo-controlled 
trial on the effect of pyridostigmine on fatigue, physical performance, and muscle 
function in selected patients with PPS. Sixty-seven ambulatory patients with PPS with 
increased fatigue and new weakness in one quadriceps muscle showing 
neuromuscular transmission defects were included. After 2 baseline measurements 
patients are randomised and treated with pyridostigmine or placebo for 14 weeks. 
Pyridostigmine is given in a dose of 60 mg four times a day. The primary outcome is 
fatigue (on the energy category of the Nottingham Health Profile). Secondary 
outcomes are walking capacity and performance, maximal quadriceps strength and 
activation, muscle fatigability and neuromuscular transmission defects of the lateral 
vastus, and the subjective benefit of treatment. The primary data analysis compares 
the changes from baseline in the outcomes in the 14th week of treatment between 
groups. Motor unit size of the quadriceps is studied as a potential effect modifier. 
Thirty-one subjects treated with pyridostigmine and 31 subjects treated with 
placebo completed the trial. Compliance of medication intake and blinding were 
sufficient. No significant effect of pyridostigmine was found on fatigue. Walking 
capacity improved more in the pyridostigmine group than in the placebo group (net 
improvement of 6.0%; P<0.01). Sub-group analysis showed that the significant 
improvement in walking capacity was only found in patients with normal sized motor 
units. There was a trend that maximal quadriceps strength improved more in the 
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pyridostigmine group than in the placebo group (net improvement of 7.2%; P=0.15). 
No effect of pyridostigmine was found on neuromuscular transmission quality, muscle 
fatigability, and subjective benefit of treatment. 
It is concluded that pyridostigmine in the prescribed dose does not reduce fatigue 
in selected patients with PPS. The significant improvement in walking capacity is less 
than considered clinically relevant. However, the significant improvement in walking 
capacity and the trend of improvement in maximal strength suggests that 
pyridostigmine may have some beneficial effect on physical performance, especially 
in subjects with neuromuscular transmission defects in normal sized motor units. 
 
The level of effort and the characteristics of walking in tests under standardized 
conditions may differ from those in daily life when conditions are not standardized. 
Furthermore, the relationship between walking capacity measured under 
standardized conditions and actual walking performance in the daily life in patients 
with PPS has never been investigated. Chapter 7 compares walking test results with 
walking in daily life, and investigates the relationships between walking tests, walking 
activity in daily life, and perceived mobility problems in patients with PPS.  
Data are derived from 24 patients with PPS who underwent ambulatory monitoring 
of their daily life activities (including walking) in the pyridostigmine trial. Walking tests 
are performed at self-preferred and maximal speed. Heart rate, step cadence and 
walking speed in the test and in daily life walking are compared. Perceived mobility 
problems are assessed with the Nottingham Health Profile, category physical 
mobility. 
It was found that heart rate was significantly lower during walking in the test at self-
preferred speed than during walking in daily life. No difference in step cadence was 
found. Self-preferred walking speed in the test correlated significantly with walking 
speed in daily life. In a sub-group of patients with a walking capacity below the 
median value, test performance correlated significantly with the duration of walking 
activity in daily life. No significant correlation was found between perceived mobility 
problems and walking activity in daily life. 
It is concluded that walking in daily life may be more demanding than walking 
under standardized conditions. Patients do not necessarily adapt their activity pattern 
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to their perceived mobility problems. Only in patients with low walking capacity, 
walking capacity influences their daily life walking behaviour. 
 
The discussion in Chapter 8 critically focuses on the methodology of the randomised 
clinical trial, discusses the clinical implications of its results, emphasizes the 
importance of measuring performance in a standardized environment, and gives 
recommendations for future research. In the trial no relevant beneficial effect of 
pyridostigmine was found in selected patients with PPS. The negative results can be 
due to clinimetric limitations of the fatigue questionnaires and the outcome measures 
of muscle function, as was described in Chapters 3, 4 and 6. However, this is unlikely 
because no effect was found on any outcome of fatigue, and the mean changes on all 
outcomes of fatigue and muscle function were small. Another explanation might be 
that the assumption, on which the trial was based, namely, that the neuromuscular 
transmission defects are responsible for the increased fatigue, was wrong. There can 
be several other causes of fatigue, and transmission failures may not have been the 
primary cause in some patients. 
 
Based on the results presented in Chapter 7, an additional sub-group analysis was 
performed for walking capacity. It appeared that patients with low walking capacity 
(<50th percentile in the walking test at maximal speed), when treated with 
pyridostigmine, improved significantly more on fatigue measured with the Fatigue 
Severity Scale, on both self-preferred and maximal walking speed, and on maximal 
quadriceps strength and activation, compared to patients who received placebo. No 
significant effects of pyridostigmine were found in patients with high maximal walking 
capacity. The walking performance of patients with low walking capacity may be 
strongly determined by their limited capacity to generate muscle strength, which may 
improve while pyridostigmine improves the neuromuscular transmission. Therefore, 
in these patients, pyridostigmine may have a beneficial effect on fatigue and walking 
capacity by improving the factor that primarily limits physical functioning, i.e. muscle 
strength. The improvements in strength and voluntary activation are substantial 
(respectively 20% and 13%) and may have clinical relevance for some patients. The 
walking performance of patients with greater walking capacity is probably more 
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determined by personal and environmental factors. These results suggest that 
pyridostigmine can not be ruled out as a treatment option to improve muscle function 
and performance in patients with PPS who have little muscle strength (that limits their 
daily life walking), severe fatigue and demonstrated neuromuscular transmission 
defects.  
 
Due to the wide measurement variability, at the individual level outcome measures of 
fatigue and muscle function lack precision to reliably determine the severity of 
impairments, and lack the sensitivity to identify changes over time. The good test-
retest reproducibility of the walking tests, and the significant correlation between 
walking test results and daily life walking performance (Chapter 7), emphasize the 
importance of evaluating capacities, i.e. abilities in a standardized environment. 
Measurements of capacities may hold an important position between impairments of 
body functions on the one hand, and functioning in daily life on the other hand. 
Furthermore, in our trial, maximal walking capacity discriminated between sub-groups 
with respect to response to pyridostigmine. Standardized measurements to evaluate 
capacities may contribute to a better understanding of the underlying problems, and 
may provide clues for developing intervention strategies aimed at improving the 
performance of daily life activities within the environmental and personal context.  
 
Future research should target to gain more insight into the complex phenomenon of 
fatigue in PPS. Aims should be to investigate whether different forms of fatigue in 
patients with PPS can be distinguished, to identify the determinants of fatigue 
(particularly with respect to neuromuscular transmission defects), and to determine 
the impact of fatigue on daily functioning. To investigate these issues, a descriptive 
study in a large unselected population of patients with PPS is required. Treatment 
studies with pyridostigmine should concentrate on patients, whose functional 
deterioration is primarily caused by transmission defects. The dose of medication 
should be individually adjusted and outcome measures should focus on the 
evaluation of performance, both in a standardized and in a daily environment. The 
clinical relevance of pyridostigmine for PPS patients with poor walking capacity, due 
to low muscle strength, needs to be confirmed in further studies. 
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n het verleden werd aangenomen dat de neurologische restverschijnselen van 
polio stabiel zouden blijven gedurende het leven. Echter, eind jaren zeventig en 
begin jaren tachtig van de vorige eeuw uitten grote aantallen voormalige slachtoffers 
van de polio-epidemieën uit de jaren ’40 en ’50 klachten over nieuwe 
neuromusculaire symptomen. Uit inventariserende studies kwam naar voren dat de 
belangrijkste symptomen waren: nieuwe spierzwakte, abnormale spiervermoeidheid, 
spieratrofie, en spier- en gewrichtspijn. Deze symptomen werden gedefinieerd als het 
postpoliomyelitis syndroom (PPS). PPS is langzaam progressief en belemmert het 
dagelijks functioneren. De voornaamste problemen voor patiënten zijn vermoeidheid 
en afname van fysieke mobiliteit, waardoor de onafhankelijkheid en kwaliteit van 
leven afnemen. 
 
Poliomyelitis is een infectieziekte die wordt veroorzaakt door het poliovirus dat 
primair de motorische neuronen in het ruggenmerg aantast. Dit leidt tot een acute, 
slappe verlamming waarbij een wisselend aantal spiergroepen is aangedaan. Herstel 
treedt op doordat aangetaste motorische neuronen die de acute fase van polio 
hebben doorstaan de functie hervatten. Verder treedt reïnnervatie van spiervezels 
van afgestorven motorische neuronen op door vorming van nieuwe zenuwuitlopers 
van nog intacte axonen (collaterale sprouting). Dit leidt tot toename van grootte van 
motor units. Tot slot treedt hypertrofie van spiervezels op waarmee het verlies in 
spierkracht verder wordt gecompenseerd. Aan het einde van de herstelfase resteert 
een stabiele parese die gedurende tientallen jaren niet verandert. 
Er wordt verondersteld dat de vergrote motor units die zijn ontstaan na de acute 
polio aanvankelijk stabiel functioneren maar na zo’n 30 tot 40 jaar vroegtijdig 
degenereren. De hypothese is dat dit het gevolg is van de hoge metabole belasting 
van de motorische neuronen die immers grote motor units moeten onderhouden. De 
degeneratie van motor units resulteert in een langzaam progressief verlies van 
zenuwuiteinden en een geleidelijke afname van spierkracht. Er zijn aanwijzingen dat 
voorafgaand aan de degeneratie van de zenuwuiteinden neuromusculaire 
transmissiestoornissen ontstaan, die kunnen leiden tot symptomen zoals toename 
van vermoeidheid en afname van het uithoudingsvermogen. Studies die gebruik 
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maakten van stimulatie single-fibre elektromyografie hebben het bestaan van 
transmissiestoornissen ter hoogte van het motorisch eindplaatje bevestigd. 
In 1993 suggereerden Trojan en Cashman dat de transmissiestoornissen het 
gevolg kunnen zijn van het onvoldoende aanmaken en vrijkomen van de 
neurotransmitter acetylcholine. Trojan en co-auteurs bestudeerden het effect van de 
anticholinesteraseremmer pyridostigmine dat de werkzaamheid van acetylcholine 
verlengt. In de door hen opgezette gerandomiseerde gecontroleerde multicenter 
studie werd echter geen effect aangetoond van het dagelijks gebruik van 180 mg 
pyridostigmine gedurende 6 maanden op fysiek functioneren, spierkracht en 
vermoeidheid. Het negatieve resultaat van deze trial zou echter het gevolg kunnen 
zijn van methodologische beperkingen met betrekking tot de selectie van patiënten, 
gekozen uitkomstmaten, en toegepaste dosering van pyridostigmine. 
De brief aan de editor van Neurology in hoofdstuk 2 is een reactie op de resultaten 
gepubliceerd door Trojan en coauteurs en zet kanttekeningen bij de methodologie en 
het design van hun trial. De kritiek richt zich in het bijzonder op de beperkte 
responsiviteit van de uitkomstmaten en de heterogeniteit van de patiëntenpopulatie in 
de studie. In de brief wordt geconcludeerd dat op basis van de resultaten van de trial 
van Trojan en coauteurs, pyridostigmine niet kan worden uitgesloten als een mogelijk 
zinvolle behandeling voor patiënten met PPS. Dit was een stimulans om een reeds in 
voorbereiding zijnde trial naar het effect van pyridostigmine op de symptomen van 
PPS daadwerkelijk uit te voeren. In vergelijking met de trial van Trojan en coauteurs 
zijn de belangrijkste methodologische verschillen dat symptoom-specifieke 
uitkomstmaten zijn toegepast, een homogene patiënten groep is samengesteld en 
dat de dosering is verhoogd tot 240 mg pyridostigmine per dag. 
 
In de hoofdstukken 3, 4 en 5 wordt de validiteit en reproduceerbaarheid beschreven 
van de belangrijkste uitkomstmaten toegepast in de trial: vermoeidheidsvragenlijsten, 
maximale spierkracht metingen en loopprestatie testen. Bij 65 patiënten met PPS zijn 
2 baseline metingen uitgevoerd, met een interval van 3 weken, waarbij vermoeidheid, 
spierkracht en loopprestatie zijn bepaald. 
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In het verleden zijn verschillende vragenlijsten gebruikt om vermoeidheid bij 
patiënten met PPS te meten. Het is een probleem om de resultaten verkregen met 
verschillende vragenlijsten met elkaar te vergelijken omdat niet duidelijk is of de 
verschillen in scores daadwerkelijk verschillen in vermoeidheid uitdrukken, of dat ze 
verschillen in response karakteristieken tussen de vragenlijsten weerspiegelen. 
Daarnaast is niet bekend wat de gevoeligheid is van vragenlijsten om verandering in 
vermoeidheid bij patiënten met PPS te detecteren. 
In hoofdstuk 3 is de vergelijkbaarheid en reproduceerbaarheid onderzocht van 4 
vragenlijsten die vaak worden gebruikt om de ernst van vermoeidheid bij patiënten 
met PPS te bepalen: de Fatigue Severity Scale (FSS; schaalbereik 1-7), de 
Nottingham Health Profile (NHP) categorie energie (schaalbereik 0-100), de Polio 
Problem List (PPL) item vermoeidheid (schaalbereik 0-7), en de Dutch Short Fatigue 
Questionnaire (SFQ; schaalbereik 1-7). 
De gemiddelde, genormaliseerde totaalscores op de 2e baseline meting waren het 
hoogst (=ernstig vermoeid) voor het PPL item vermoeidheid (81±17% van de 
schaalrange), en het laagst voor de NHP categorie energie (47±35%). De correlaties 
tussen de scores van de vragenlijsten waren allen significant en lagen tussen r=.43 
voor de NHP categorie energie en het PPL item vermoeidheid, en r=.68 voor het PPL 
item vermoeidheid en de SFQ. De vermoeidheidscores verschilden significant tussen 
de vragenlijsten, behalve tussen de FSS en het PPL item vermoeidheid. Mokken 
Schaal Analyse ter bepaling van de construct validiteit toonde aan dat alle 
vragenlijsten hetzelfde unidimensionele construct maten. De reproduceerbaarheid 
van de FSS, het PPL item vermoeidheid, en de SFQ was matig. De kleinst 
detecteerbare verandering was 1.5 schaalpunt voor de FSS, en 2 schaalpunten voor 
het PPL item vermoeidheid en de SFQ.  
De conclusie is dat, bij patiënten met PPS, alle vragenlijsten hetzelfde 
vermoeidheidconstruct meten, maar dat de score voor vermoeidheid, een maat voor 
de ernst ervan, aanzienlijk kan verschillen als gevolg van verschillen in bereik 
waarbinnen de vragenlijsten vermoeidheid meten. De matige reproduceerbaarheid 
van de vragenlijsten duidt op gebrek aan precisie, vooral wanneer de lijsten worden 
gebruikt op individueel niveau. 
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In lange termijn studies is de afname in spierkracht van patiënten met PPS geschat 
op 1 à 2% per jaar. Het is daarom de vraag of een individuele afname in kracht 
binnen een periode van slechts enkele jaren kan worden aangetoond. Het is 
onbekend wat het vermogen van een vaste dynamometer is om een verandering in 
kracht te detecteren bij (individuen met) PPS. Bij personen die in het verleden polio 
hebben doorgemaakt is verminderde maximale vrijwillige spier activatie 
geconstateerd. Variabiliteit in activatie leidt tot variabiliteit in kracht, en kan daardoor 
bijdragen aan de variabiliteit in spierprestatie. In hoofdstuk 4 is de kleinst 
detecteerbare verandering in maximale kracht bepaald in een symptomatische 
musculus quadriceps van patiënten met PPS, en is de associatie onderzocht tussen 
variabiliteit in maximale kracht en maximale vrijwillige activatie. 
Vrijwillige isometrische piekkracht is gemeten bij een optimale kniehoek, en 
maximale vrijwillige activatie is bepaald door middel van twitch-interpolatie. Het 
verschil in kracht tussen de 2 baseline metingen voor de gehele groep was klein en 
niet significant. De test-hertest betrouwbaarheid was uitstekend voor maximale kracht 
(ICC=.96) en matig voor maximale vrijwillige activatie (ICC=.73). De kleinste afname 
in kracht die op groepsniveau (n=65) gedetecteerd kan worden was 4.5%. Op 
individueel niveau kan een afname van ten minste 25% worden gedetecteerd. De 
gemiddelde maximale vrijwillige activatie bedroeg 67% van volledige activatie. De 
variabiliteit in maximale vrijwillige activatie verklaarde 18% van de variabiliteit in 
kracht. 
De conclusie luidt dat de variabiliteit in maximale quadriceps kracht, gemeten met 
een vaste dynamometer, groot is, en slechts deels gerelateerd is aan de variabiliteit 
in maximale activatie. Dit impliceert dat, zelfs onder optimale gestandaardiseerde 
omstandigheden, het met een vaste dynamometer niet mogelijk is om kleine 
veranderingen in spierkracht in een symptomatische quadriceps van individuele 
patiënten met PPS te detecteren. De reproduceerbaarheid is wel toereikend om in 
follow-up studies van ten minste 4 jaar veranderingen in groepen patiënten te kunnen 
evalueren en om in interventie studies klinisch relevante effecten te kunnen 
aantonen. De beperkte invloed van variabiliteit in maximale vrijwillige activatie op 
variabiliteit in kracht kan worden veroorzaakt door de curvilineaire relatie tussen 
vrijwillige activatie en kracht, of door coactivatie van de hamstrings. 
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Loopprestatie wordt meestal gemeten met tijdgescoorde looptesten. Of zulke testen 
geschikt zijn om een afname in loopprestatie te bepalen hangt in grote mate af van 
hun reproduceerbaarheid. De intensiteit van fysieke inspanning tijdens lopen kan 
objectief worden gemeten aan de hand van de hartslagfrequentie, maar ook door het 
scoren van de ervaren belasting. Recentelijk is aanbevolen om patiënten met PPS 
een Borg schaal te laten gebruiken om ervaren inspanning te scoren met als doel 
ernstige vermoeidheid te voorkomen. Of een dergelijke schaal geschikt is voor dit 
doel hangt af van de reproduceerbaarheid en of de scores gerelateerd zijn aan de 
daadwerkelijke inspanning en prestatie. Hoofdstuk 5 beschrijft de 
reproduceerbaarheid van, en de associaties tussen loopvaardigheid, 
hartslagfrequentie en ervaren inspanning, tijdens looptesten op comfortabele en 
maximale snelheid in patiënten met PPS. 
De test-hertest betrouwbaarheid van loopvaardigheid was uitstekend voor beide 
testen (ICC range, .94-.97). De kleinst detecteerbare verandering voor een individu 
bedroeg 15% voor beide testen. De test-hertest betrouwbaarheid was goed voor 
hartslagfrequentie (ICC=.86) en matig voor ervaren inspanning (Spearman ρ range 
.67–.70). De kleinst detecteerbare verandering in ervaren inspanning lag tussen 4 en 
6 schaalpunten. De variabiliteit in loopvaardigheid was significant gecorreleerd met 
de variabiliteit in hartslagfrequentie, maar niet met de variabiliteit in ervaren 
inspanning. 
De goede reproduceerbaarheid van beide looptesten is toereikend om 
(individuele) veranderingen in loopprestatie van patiënten met PPS aan te kunnen 
tonen. Omdat de reproduceerbaarheid tussen beide looptesten niet verschilt, kan een 
eventuele keuze tussen beide testen gebaseerd worden op andere criteria. Vanwege 
de matige reproduceerbaarheid lijkt een Borg schaal geen geschikt instrument om de 
mate van fysieke inspanning bij patiënten met PPS te bepalen, en om te gebruiken 
als methode om overbelasting te voorkomen. 
 
In Hoofdstuk 6 worden de resultaten gepresenteerd van het gerandomiseerde, 
dubbelblinde, placebo-gecontroleerde onderzoek naar het effect van pyridostigmine 
op vermoeidheid, fysieke prestatie en spierfunctie in geselecteerde patiënten met 
PPS. Zevenenzestig ambulante patiënten met PPS met vermoeidheid en symptomen 
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van nieuwe spierzwakte in ten minste 1 quadriceps met aangetoonde 
neuromusculaire transmissiestoornissen, zijn geïncludeerd. Na 2 baseline metingen 
worden de patiënten gerandomiseerd en behandeld met pyridostigmine of placebo 
gedurende 14 weken. Pyridostigmine is gegeven in een dosering van 4 maal daags 
60 mg. De primaire uitkomstmaat is vermoeidheid (Nottingham Health Profile, 
categorie energie). Secundaire uitkomstmaten zijn loopvaardigheid en loopactiviteit, 
maximale kracht en vrijwillige activatie van de quadriceps, spiervermoeibaarheid en 
neuromusculaire transmissiestoornissen van de vastus lateralis, en het subjectieve 
effect van de behandeling. De primaire data-analyse vergelijkt de veranderingen in 
de uitkomstmaten in de 14e week van de behandeling ten opzichte van baseline 
tussen de groepen. Motor unit grootte van de quadriceps wordt bestudeerd als 
potentiële effect modificator. 
Eenendertig patiënten behandeld met pyridostigmine en 31 patiënten behandeld 
met placebo voltooiden de trial. De therapietrouw was hoog en de blindering was 
goed. Er werd geen significant effect van pyridostigmine gevonden op vermoeidheid. 
De loopvaardigheid verbeterde meer in de pyridostigmine groep dan in de placebo 
groep (verschil in verbetering: 6%; P<0.01). Subgroepanalyse toonde aan dat alleen 
patiënten met een normale motor unit grootte significant verbeterden in 
loopvaardigheid. Er was een trend dat de maximale quadriceps kracht sterker 
toenam in de pyridostigmine groep dan in de placebo groep (verschil in verbetering: 
7.2%; P=0.15). Er werd geen effect van pyridostigmine gevonden op de kwaliteit van 
de neuromusculaire transmissie, op spiervermoeibaarheid, en op het subjectieve 
effect van de behandeling.  
De conclusie luidt dat pyridostigmine in de voorgeschreven dosering vermoeidheid 
niet vermindert in geselecteerde patiënten met PPS. De significante verbetering in 
loopvaardigheid is klein en wordt niet als klinisch relevant beschouwd. Echter, de 
significante verbetering in loopvaardigheid en de trend van verbetering in maximale 
kracht suggereren dat pyridostigmine een gering positief effect heeft op fysiek 
presteren, in het bijzonder in patiënten met neuromusculaire transmissiestoornissen 
in motor units met een normale grootte. 
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Het niveau van inspanning en loopkarakteristieken tijdens looptesten onder 
gestandaardiseerde omstandigheden kunnen afwijken van die in het dagelijks leven 
waar omstandigheden niet gestandaardiseerd zijn. Daarnaast is de relatie tussen 
loopvaardigheid, gemeten onder gestandaardiseerde condities, en de daadwerkelijke 
loopactiviteit in het dagelijks leven niet eerder onderzocht in patiënten met PPS. In 
Hoofdstuk 7 worden karakteristieken van lopen in een looptest vergeleken met die 
tijdens lopen in het dagelijks leven, en wordt de relatie beschreven tussen looptesten, 
loopactiviteit in het dagelijks leven, en ervaren mobiliteitsproblemen in patiënten met 
PPS.  
Data zijn afkomstig van 24 deelnemers aan de pyridostigmine trial waarbij 
ambulante metingen zijn verricht van activiteiten in het dagelijks leven (waaronder 
lopen). Looptesten zijn uitgevoerd op comfortabele en op maximale snelheid. 
Hartslagfrequentie, stapfrequentie en loopsnelheid in de test en in het dagelijks leven 
zijn vergeleken. Ervaren mobiliteitsproblemen zijn gemeten met de Nottingham 
Health Profile, categorie fysieke mobiliteit. 
De hartslagfrequentie was tijdens het lopen in de test op comfortabele snelheid 
significant lager dan tijdens lopen in het dagelijks leven. Er werd geen verschil in 
stapfrequentie gevonden. De comfortabele loopsnelheid in de test correleerde 
significant met loopsnelheid in het dagelijks leven. In een subgroep van patiënten met 
een loopvaardigheid beneden de mediaan correleerde loopprestatie in de tests 
significant met de duur van loopactiviteit in het dagelijks leven. Er werd geen 
significante correlatie gevonden tussen ervaren mobiliteitsproblemen en loopactiviteit 
in het dagelijks leven.  
De conclusie is dat lopen in het dagelijks leven mogelijk meer inspanning vergt 
dan lopen onder gestandaardiseerde omstandigheden. Patiënten passen hun 
activiteitenpatroon niet onvoorwaardelijk aan aan hun ervaren mobiliteitsproblemen. 
Loopvaardigheid lijkt alleen invloed te hebben op het dagelijks loopgedrag van 
patiënten met een verminderde loopvaardigheid. 
 
De discussie in hoofdstuk 8 evalueert de gebruikte methodologie in de 
gerandomiseerde klinische trial, bediscussieert de klinische implicaties van de 
verkregen resultaten, benadrukt het belang van het meten van fysieke prestatie in 
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een gestandaardiseerde omgeving, en doet aanbevelingen voor toekomstig 
onderzoek. In de trial is geen klinisch relevant effect van pyridostigmine gevonden in 
geselecteerde patiënten met PPS. Het negatieve resultaat kan een gevolg zijn van 
klinimetrische beperkingen van de vermoeidheidsvragenlijsten en de uitkomstmaten 
voor spierfunctie, zoals is beschreven in de hoofdstukken 3, 4 en 6. Dit is echter 
onwaarschijnlijk omdat geen enkele uitkomstmaat van vermoeidheid een effect laat 
zien, en omdat de gemiddelde veranderingen op alle uitkomstmaten van 
vermoeidheid en spierfunctie gering zijn. Overwogen moet worden of de assumptie 
waarop de trial was gebaseerd, namelijk, dat neuromusculaire 
transmissiestoornissen verantwoordelijk zijn voor de ervaren vermoeidheid, juist is. 
Er zijn meerdere oorzaken voor vermoeidheid beschreven, en transmissiestoornissen 
hoeven niet de primaire oorzaak te zijn geweest in de PPS patiënten die aan de trial 
deelnamen. 
 
Gebaseerd op de gevonden samenhang tussen loopvaardigheid en loopactiviteit in 
het dagelijks leven in hoofdstuk 7, is een aanvullende subgroepanalyse uitgevoerd op 
basis van loopvaardigheid. Hieruit kwam naar voren dat patiënten met een beperkte 
loopvaardigheid (<50ste percentiel in de looptest op maximale snelheid) behandeld 
met pyridostigmine, in vergelijking met patiënten behandeld met placebo, significant 
meer verbeteren in vermoeidheid gemeten met de Fatigue Severity Scale, in zowel 
comfortabele als maximale loopsnelheid, en in maximale kracht en activatie van de 
quadriceps. Daarentegen werd geen enkel significant effect van pyridostigmine 
gevonden bij patiënten met een betere maximale loopvaardigheid (>50ste percentiel in 
de looptest op maximale snelheid). De prestatie van patiënten met een beperkte 
loopvaardigheid wordt mogelijk sterk bepaald door hun beperkte capaciteit om kracht 
te leveren. Het is mogelijk dat pyridostigmine door het verbeteren van de 
neuromusculaire transmissie bij deze patiënten een gunstig effect heeft op 
vermoeidheid en loopvaardigheid doordat de spierkracht verbetert die in belangrijke 
mate hun fysiek functioneren bepaalt. De verbetering in kracht en vrijwillige activatie 
is aanzienlijk (respectievelijk 20% en 13%) en kan als klinisch relevant worden 
beschouwd. De loopprestatie van patiënten met een betere loopvaardigheid wordt 
waarschijnlijk meer bepaald door andere factoren dan spierkracht zoals persoonlijke 
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factoren en omgevingsfactoren. Deze resultaten maken duidelijk dat pyridostigmine 
niet mag worden uitgesloten als een behandelmogelijkheid om spierfunctie en 
prestatie te verbeteren bij bepaalde patiënten met PPS. Het betreft die patiënten met 
dusdanig weinig spierkracht dat het lopen in het dagelijks leven wordt beperkt, en 
met ernstige vermoeidheid en aantoonbare neuromusculaire transmissiestoornissen. 
 
Als gevolg van de grote variatie in meetresultaten op individueel niveau, missen 
uitkomstmaten van vermoeidheid en spierfunctie voldoende precisie om de ernst van 
afwijkingen betrouwbaar te kunnen meten, en zijn ze onvoldoende gevoelig om 
veranderingen in de tijd te kunnen detecteren. De goede test-hertest 
betrouwbaarheid van de looptesten, en de gevonden associatie tussen 
looptestresultaten en loopprestatie in het dagelijks leven (hoofdstuk 7), benadrukken 
het belang van het evalueren van capaciteiten, ofwel, vaardigheden in een 
gestandaardiseerde omgeving. Uitkomstmaten op het niveau van capaciteiten 
kunnen een belangrijke positie innemen tussen stoornissen van lichaamsfuncties aan 
de ene kant, en het functioneren in het dagelijks leven aan de andere kant. 
Bovendien blijkt maximale loopcapaciteit in onze trial te discrimineren tussen 
subgroepen ten aanzien van de effectiviteit van pyridostigmine. Gestandaardiseerde 
metingen om capaciteiten te evalueren kunnen bijdragen aan een beter begrip van 
onderliggende problemen, en kunnen handvatten bieden voor het ontwikkelen van 
interventiestrategieën gericht op het verbeteren van het functioneren in het dagelijks 
leven, binnen de context van het individu en zijn omgeving.  
 
Toekomstig onderzoek zou als doel moeten hebben meer inzicht te krijgen in het 
complexe fenomeen van vermoeidheid bij PPS. Doelstellingen daarbij zijn het 
onderzoeken of verschillende vormen van vermoeidheid bij PPS kunnen worden 
onderscheiden, het identificeren van de determinanten van vermoeidheid (in het 
bijzonder met betrekking tot neuromusculaire transmissiestoornissen), en het 
bepalen van de impact van vermoeidheid op het dagelijks functioneren. Het 
beantwoorden van deze onderzoeksvragen vereist een descriptieve studie in een 
grote niet-geselecteerde populatie van patiënten met PPS. Effectstudies met 
pyridostigmine zouden zich moeten concentreren op patiënten bij wie de functionele 
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achteruitgang primair wordt veroorzaakt door transmissiestoornissen. De dosering 
van de medicatie moet individueel worden afgestemd en uitkomstmaten moeten 
gericht zijn op het evalueren van fysieke prestaties, zowel in een 
gestandaardiseerde, als in een dagelijkse omgeving. De klinische relevantie van 
behandeling met pyridostigmine bij patiënten met PPS met een verminderde 
loopvaardigheid als gevolg van een lage spierkracht moet worden bevestigd in 
vervolgstudies. 
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k ben tijdens het schrijven van mijn proefschrift aan veel zaken niet of onvoldoende 
toegekomen. Het bedanken voor de hulp die ik gaandeweg van veel mensen heb 
gekregen is er daar één van. 
Mijn grootste dank gaat uit naar de deelnemers aan het onderzoek die vaak verre 
reizen maakten, en hitte, koude en ernstige vermoeidheid trotseerden om afgemat te 
worden op de KinCom (spierkrachtmetingen) en in de patio (looptesten). U heeft mij 
versteld doen staan van uw doorzettingsvermogen, en uw vastberadenheid om te 
bereiken wat u voor ogen heeft. Deze eigenschappen hebben ertoe bijgedragen dat 
het onderzoek kon uitgroeien tot dit proefschrift, maar het zijn ook eigenschappen die 
door het risico van overbelasting voor u tot ernstige fysieke klachten kunnen leiden. 
Pas goed op uzelf!  
Professor doctor Nollet, beste Frans. Het moet een goed gevoel geven om het 
resultaat te zien van het gevolg dat is gegeven aan je ideeën van destijds. Wat ooit 
begon als een opgedragen presentatie op een bijeenkomst van revalidatieartsen is 
uitgegroeid tot een ware onderzoekslijn waar je terecht trots op mag zijn. Ondanks de 
vele afslagen die we hebben genomen wist jij altijd de goede weg terug te vinden. Je 
hebt me laten inzien dat de boodschap in een artikel voorop moet staan. Je hebt 
verbanden leggen tot een kunst verheven, en je hebt aangetoond dat goed altijd 
beter kan. Kortom, ik heb veel van je geleerd, een enkele keer ook hoe het niet moet. 
Het enthousiasme en de gedrevenheid waarmee jij je hebt ingezet om het project te 
laten slagen heb ik altijd enorm gewaardeerd. 
Anita Beelen, beste Anita, jouw hulp is van onschatbare waarde geweest. Je wist 
feilloos, maar altijd op een positieve manier, de zwakke plekken in mijn redeneringen 
bloot te leggen. Ik denk met veel plezier terug aan onze gesprekken, waarin jij vaak 
tevens als tolk fungeerde en de ideeën van Frans voor me verduidelijkte. Met je 
brede kennis, scherpe blik en zachte karakter ben je een verrijking voor elke 
onderzoeksafdeling, jammer dat we geen collega’s meer zijn. 
Professor doctor Lankhorst, beste Guus, bedankt voor de vrijheid die je me gaf en 
voor het bijsturen van de richting wanneer dat nodig was. 
Veel dank gaat ook uit naar de mensen van de afdeling Klinische Neurofyiologie 
van het Universitair Medisch Centrum Nijmegen. Gea Drost, Henny Janssen, Maartje 
Schillings, Machiel Zwarts, Jaco Pasman, Dick Stegeman, Hans van Dijk, en May 
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Eikholt-Rutten, bedankt voor het verzorgen van de metingen in Nijmegen en het 
becommentariëren van de artikelen. Ondanks de ingewikkelde en weinig 
aantrekkelijke metingen die deelnemers in Nijmegen moesten ondergaan, waren zij 
vaak vol lof over de wijze waarop zij door jullie zijn begeleid en bijgestaan. Het 
geringe aantal uitvallers is mede aan jullie te danken. 
Ik dank Haske van Veenendaal en de Vereniging Spierziekten Nederland voor hun 
inzet bij het werven van deelnemers. Marianne de Visser dank ik voor haar hulp bij 
het (vaak uit haar hoofd) screenen van statussen, het meedenken bij het opstellen 
van het protocol, en het becommentariëren van het trial artikel. 
Ik dank Hans Bussmann voor zijn hulp bij het uitwerken van de gegevens van de 
activiteiten monitor, en zijn bijdrage aan hoofdstuk 7, maar bovenal voor zijn rol in 
mijn overstap naar het Erasmus. Stagiaires Evaline, Sandra en Anoek dank ik voor 
hun hulp bij het uitvoeren en analyseren van een deel van de activiteiten registraties. 
Ik dank alle kamergenoten die mij vergezelden aan de VU, in het bijzonder 
Janneke, Merel, Jeanine en Vanessa. Ik denk met veel plezier terug aan de 
onderonsjes over het Nederlands elftal, samenwonen, verbouwingen aan huizen en 
uitgaan in het kwadraat. Als het mij lukt, moet het jullie zeker lukken. 
Caroline Doorenbosch en Jaap Harlaar, bedankt voor jullie adviezen en voor het 
coördineren van alle lab-activiteiten. Monique Heslenfeld en Vicky Kwaaitaal dank ik 
voor hun hulp bij het regelen van de meest uiteenlopende zaken. 
Een belangrijke steun de afgelopen 2 jaar waren de collega’s van het Erasmus 
Medisch Centrum (revalidatie) die zo vaak belangstelling toonden en me 
aanmoedigden het af te maken. Ik hoop dat we samen veel mogen bereiken, en 
elkaar ook naast het werk nog vaak mogen treffen in de Ardennen of in een 
Rotterdamse kroeg. Henk Stam, bedankt voor het vertrouwen dat je me gaf. 
Paranimfen Anja en Maurice, geweldig dat jullie me willen begeleiden. Beste zus, 
de cirkel is rond, leuk om ook eens aan de andere kant te mogen staan. Maurice, 
vriend van het eerste uur, dat we dit nog mogen meemaken. Ik ben blij dat je weer 
een beetje in de buurt bent. 
Remco, goede vriend en recensent, dank je voor het doorlezen van het proefschrift 
en je betrokkenheid. Ik hecht grote waarde aan je mening. Ik hoop dat ik ooit iets kan 
betekenen in het verwezenlijken van wat we ooit op een pseudo-bierviltje schreven. 
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Tot slot, Sacha, lieve vriendin. Jouw onaflatend vertrouwen overtuigde mij dat het 
echt moest kunnen. Ik ben trots op de manier waarop je ons de afgelopen jaren hebt 
laten samenleven. Ik hoop dat we samen nog veel mogen ontdekken aan het leven. 
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